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The maturation process of many prohormone molecules typically requires 





terminal of the α-melanocyte stimulating hormone (α-MSH) sequence in Silurana 
tropicalis proopiomelanocortin (POMC).  In order to determine the absolute requirement 
of basic amino acid residues in the cleavage process, site-directed mutagenesis was 
employed to substitute alanine for the wild-type residues in the frog POMC open reading 













↓.  The mouse pancreatic αTC1.9 cell line, 
which expresses prohormone convertase 2 (PC2), was selected as the model system for 
transfection studies.  The processing of wild-type frog POMC was correctly predicted to 
mimic that observed in the intermediate pituitaries of the frog.  Moreover, biochemical 





, but not of R
137
, disrupted endoproteolytic cleavage resulting in a JP-α-MSH 
mutant fusion protein.  Quantitative real-time PCR analysis of the αTC1.9 cells detected 
the relative gene expression levels of mouse PC2, glucagon but not PC1/3; detection of S. 
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Overview of Neuropeptide Biosynthesis 
Neuropeptides constitute peptide neurotransmitters as well as peptide hormones 
and represent a diverse class of signaling molecules that induce biological effects in their 
target cells by binding and activating their cognate surface receptors.  The range of 
cellular responses is very broad and includes cellular proliferation, differentiation, 
chemical communication, secretion and the regulation of various endocrine functions.  
These neuropeptides typically exist as fragments within their full length, inactive 
precursors and are released through posttranslational endoproteolytic processing during 
transport through the constitutive or regulated secretory system.  The flanking dibasic 
residues serve as cleavage sites for subtilisin-like prohormone convertases and/or 
cysteine proteases, mediated by cathepsin L (Hook et al., 2008), that cleave preferentially 
N-terminal and C-terminal of basic residues, respectively.  However, monobasic and 
tetrabasic cleavage sites also exist.  The subsequent removal of the remaining basic 
amino acids from the peptide intermediate is mediated by either aminopeptidases or 
carboxypeptidases (Hook et al., 2008).  Preceding these posttranslational maturation 
steps is the cotranslational removal of the signal peptide following translocation into the 
endoplasmic reticulum (ER).  The final step in the neuropeptide biosynthetic pathway 




sulfonation and phosphorylation (Rholam and Fahy, 2009) that further contribute to the 
functional and structural heterogeneity of the liberated bioactive molecules. 
POMC and Opioid/Orphanin Gene Family 
 Proopiomelanocortin (POMC) together with proenkephalin, prodynorphin and 
proorphanin are polypeptide precursors that collectively belong to the opioid/orphanin 
gene family.  The encoded bioactive end-products include the enkephalins, the 
dynorphins, β-endorphin and orphanin, which are individually produced from distinct 
neurons where they function as inhibitory neuropeptides in the central nervous system.  
Characteristically, these neuropeptide products exhibit preferential binding to their 
cognate receptors and regulate various physiological processes including analgesia 
(Danielson and Dores, 1999; Dores et al., 2002).  Defining features of the 
opioid/orphanin system of precursors include the shared Y/FGGF core sequence, the 
presence of several conserved N-terminal cysteine residues and at least one opioid-
containing sequence flanked by dibasic residues (Figure 1) (Danielson and Dores, 1999; 
Dores et al., 2002).  As such, the similarities in the structural organization suggest a 
mutual origin for members of opioid/orphanin family. 
 The Proenkephalin Hypothesis postulates that the opioid/orphanin family 
members were derived from a common ancestral proenkephalin-like gene through a 
series of sequential gene duplication events (Figure 2) that transpired during the evolution 
of the chordates (Figure 3) (Dores et al., 2005).  Two successive genome duplication 





 Figure 1.  Comparison of the opioid/orphanin gene family members.  Conserved cysteine 
residues, opioid and relic opioid core sequences are indicated.  Abbreviation: POMC, 





(jawless fish) and more recently, prodynorphin following the appearance of gnathostomes 
(true-jawed vertebrates).  Additionally, POMC and proorphanin were each subsequently 
duplicated during the age of the gnathostomes.  In contrast to prodynorphin, both POMC 
and proorphanin contain the fewest number of functional opioid sequences and are least 
similar to proenkephalin in primary sequence, which is consistent with divergence from 
earlier events (Danielson and Dores, 1999; Dores et al., 2002).  Nevertheless, the end-
result of these duplication events has been the formation of paralogously-related 
neuropeptides with diverse functions and differential tissue expression patterns. 
 In addition to housing the endogenous opioid β-endorphin sequence, POMC is 
distinct among the opioid/orphanin family members as it additionally encodes for a range 
of structurally related melanocortin peptides.  This group of neuropeptides 
characteristically contain the HFRW core sequence and is comprised of 
adrenocorticotropic hormone (ACTH), α-, β-, γ and δ-melanocyte stimulating hormone 
(MSH).  The organization of POMC has been largely conserved throughout the evolution 
of the chordates and this precursor can be found in every major class of vertebrates 
(Figure 2).  In Agnatha (jawless fish), as represented by studies on lamprey, two forms of 
POMC exist.  These include POC (proopiocortin) and POM (proopiomelanotropin), 
which are expressed exclusively in the pars distalis and pars intermedia, respectively.  
POC encodes for ACTH, β-endorphin and a relic β-MSH sequence while POM contains 
the α- and β-MSH-like sequences along with a β-endorphin sequence (Dores and Lecaudé, 
2005).  Among the gnathostomes, POMC appears to be relatively uniform among the 





Figure 2.  The Proenkephalin Hypothesis, a working hypothesis postulating the evolution 
of the opioid/orphanin gene family members based on sequential duplication events of 
the ancestral Proenkephalin-like ancestral gene during the evolution of the chordates.  
Abbreviations: POC, proopiocortin; POM, proopiomelanotropin; POMC, 





Figure 3.  Phylogenetic tree of the major vertebrate subphylum within phylum Chordata.  





Sarcopterygii (lobe-finned fish and tetrapods).  Specifically, the precursor contains at 
least three melanocortin-like sequences (ACTH/α-, β- and γ-MSH) as well as a β-
endorphin-like sequence with the exception of the teleost infraclass of Actinopterygii in 
which the γ-MSH-like sequence has become secondarily lost due to deletions (Dores et 
al., 2002; Dores and Lecaudé, 2005).  In contrast, a lineage-specific duplication event 
produced δ-MSH, a fourth melanocortin unique only to POMC among members of the 
Chondrichthys class (Dores et al., 2002; Dores and Lecaudé, 2002).  A characteristic of 
some sarcopterygian is the presence of an internal monobasic cleavage site in β-
endorphin that can yield truncated forms ranging from 8 to 10 amino acid residues.  This 
monobasic cleavage site, however, appears to be an ancestral feature of early 
sarcopterygian vertebrates, including anuran amphibians and lungfish, and are absent 
from amniote vertebrates such as turtles, birds and mammals (Dores and Lecaudé, 2005).  
In essence, the outcome has been the generation of a multifunctional precursor with 
expansive tissue expression patterns encoding various peptides with a palette of activities. 
Physiological Functions of POMC-derived Peptides 
 The pleiotropic properties of POMC-derived molecules are found across a range 
of both endocrine and non-endocrine tissue systems and typically include roles as 
neurotransmitters centrally and peptide hormones peripherally.  As with other chemical 
signals, the endogenous opioid β-endorphin and the melanocortins induce their biological 
effects through receptor binding and activation.  β-endorphin signals through the opioid µ 




(MC1-5R) family of receptors.  Both receptor types belong to the rhodopsin A family of 
G-protein-coupled receptors (GPCR) that contain 7-transmembrane spanning helical 
regions, an extracellular N-terminal and an intracellular C-terminal domain (Catania et al., 
2004; Waldhoer et al., 2004).  Signaling is mediated predominantly through the 
activation of adenyl cyclase with the consequent production of cAMP that induces 
biological activity and protein kinase activation.  However, some evidence suggests 
activity can also be coupled to inositol-phospholipid-Ca
2+
-mediated signaling, which 
represents an alternate downstream signaling avenue (Catania et al., 2004).  As such, the 
tissue expression of cognate receptors is paramount to the physiological activities of these 
peptides. 
 The analgesic effects of the opioid β-endorphin are profound and have been 
shown to be at least equipotent with morphine-induced analgesia (Kuraishi et al., 1980).  
By interactions with its cognate receptor, hypothalamic β-endorphin and pituitary-derived 
β-endorphin modulate pain in the central nervous system and in the periphery, 
respectively (Figure 4A).  Both effects are the consequence of somatosensory receptor 
inhibition (Hartwig, 1991).  Additionally, the facilitatory role of central nervous system 
β-endorphin in stimulating appetite is another area of study as demonstrated in animal 
models, such as rats (Grandison, 1977) and chicks (Yanagita et al., 2008).  However, 
only non-acetylated, full-length β-endorphin exerts biological activity as N-acetylated 
derivatives and truncated forms exhibit abrogated and reduced opiate binding capacity, 




 In contrast to β-endorphin-induced feeding behavior, the antagonistic effects of 
the central melanocortin system suppress appetite (Wilkinson, 2005) (Figure 4A, B) 
where N-acetyl- and N,O-diacetyl-α-MSH exhibit greater potency and longer biological 
half-lives relative to the non-acetylated form (Rudman et al., 1983) (Figure 4A, B).  
MC3R and MC4R are the key melanocortin receptors responsible in feeding regulation 
(Bicknell, 2008; Raffin-Sanson et al., 2003) and the importance of hypothalamic N-
acetyl-α-MSH in satiation of appetite in mice was found to be a consequence of 
upregulated POMC expression and N-acetyltransferase activity following leptin 
administration (Guo et al., 2004).  Likewise, a similar role in feeding and body weight 
regulation has also been implicated for β-MSH (Figure 4A), as revealed by screening of 
patients with early-onset diabetes (Biebermann et al., 2006; Lee et al., 2006). 
 Other functions of the melanocortins include the anti-inflammatory effects of α-
MSH (Macaluso et al., 1994) and the stimulatory influences of α-MSH, ACTH and β-
MSH on skin pigmentation through eumelanin production (Figure 4A, B) (Bicknell, 2008; 
Dores and Lecaudé, 2005; Rousseau et al., 2007).  Both processes are mediated through 
MC1R activation in an endocrine and/or paracrine/autocrine fashion as POMC, which in 
addition to being expressed in the pituitaries, is also produced peripherally in leukocytes 
(Lyons and Blalock, 1997) and in an UV-dependent manner in the skin (Bicknell, 2008; 
Raffin-Sanson et al., 2003; Rousseau et al., 2007).  Moreover, the strong binding affinity 
of α-MSH to MC5R, which is ubiquitously expressed in peripheral exocrine tissues, 







Figure 4.  Schematic of assorted endocrine and autocrine/paracrine functions of POMC-
encoded products.  (A) Overview of the major physiological functions of various POMC-
derived peptides in the hypothalamus/central nervous system and peripherally at the 
adrenal glands and skin.  Activities include but are not limited to β-endorphin-mediated 
pain control (analgesia) as well as melanocortin-dependent regulation of food intake, 
eumelanin synthesis (skin pigmentation), exocrine gland secretion, steroidogenesis and 
mitogenesis.  Cognate receptors are also included.  (B) Overview of α-MSH-induced 
physiological activities.  Endocrine functions include hypothalamic α-MSH-mediated 
inhibition of appetite and pituitary-derived ACTH-mediated steroidogenesis at the 
adrenal glands.  Also illustrated is the UV-dependent autocrine/exocrine role of α-MSH 










Yet, an intensely studied hormonal function of the melanotropic peptides is the 
steroidogenic effects of ACTH (Figure 4A, B) (Lefkowitz et al., 1970), the only 
melanocortin ligand capable of selectively binding and activating MC2R.  Activation of 
this receptor, which is heavily expressed in the zona glomeruloa and zona fasciculate of 
the adrenal cortex (Catania et al., 2004; Raffin-Sanson et al., 2003), ultimately leads to 
the synthesis and secretion of steroid hormones.  The complementary actions of the N-
terminal POMC fragment (pro-γ-MSH) and Lys-γ3-MSH augment ACTH-induced 
steroidogenesis has also been reported (Wilkinson, 2005).  This process is coupled 
through MC3R, the only melanocortin receptor with strong γ-MSH-binding affinity 
(Wilkinson, 2005).  Moreover, extracellular cleavage of the N-terminal pro-γ-MSH 
fragment produces a truncated N-terminal form (N POMC(1-52)) with mitogenic properties 
(Figure 4A) although the cognate receptor remains to be identified (Raffin-Sanson et al., 
2003).  This thereby complements the adrenal-related activities of the melanocortin 
peptides.  Essentially, the pleiotropic activities exhibited by these peptide hormones are a 
consequence of the tissue-specific processing of the encoding precursor molecule. 
Tissue-specific Processing of POMC and Posttranslational Modifications of POMC-
derived Peptides 
 
The concept that bioactive molecules are derived from larger inactive 
polypeptides is a central dogma in endocrinology and has been documented in many 
proneuropeptides including POMC.  This scheme for POMC was initially demonstrated 
through pioneering biochemical experiments that suggested both ACTH and β-LPH were 




and Herbert, 1977); however, the cloning of the POMC cDNA from bovine intermediate 
lobe (Nakanishi et al., 1979) unequivocally confirmed the presence of various 
neuropeptides interspersed within a common molecule.  Like other secretory proteins, the 
nascent POMC is targeted into the ER lumen by the signal peptide, which is subsequently 
removed cotranslationally.  Once fully synthesized, the 31-kDa POMC is thought to be 
trafficked into the regulated secretory pathway by virtue of the conserved N-terminal 
disulfide bridges (Roy et al., 1991) where precursor processing occurs coordinately with 
the maturation of the secretory granules (Tanaka et al., 1997).  The liberated bioactive 
end-products are ultimately secreted via regulated exocytosis. 
While POMC has been shown to be expressed in a range of both endocrine and 
non-endocrine tissues, the end-products generated can vary drastically; consequently, 
tissue-specific processing precisely describes the posttranslational maturation process of 
POMC.  The processing of POMC has traditionally been studied in the pituitaries and 
most tissue systems follow the archetypical processing profile of the anterior pituitary 
(pars distali) corticotrope cells or of the intermediate pituitary (pars intermedia) 
melanotrope cells (Figure 5).  The full-length POMC precursor contains eight pairs of 
dibasic residues and one tetrabasic site that are selectively cleaved in a manner 
characteristic to the tissue origin.  The basis for tissue-specific processing of POMC has 
been shown to be a consequence of the differential tissue expression patterns and 





In both mammalian and non-mammalian pituitary corticotropes where PC2 levels 
are typically negligible relative to the predominant expression of PC1/3, POMC is 
preferentially cleaved at four of the dibasic sites.  As such, the major end-products 
include a 16-kDa N-terminal fragment (pro-γ-MSH), ACTH and β-lipotrophin (β-LPH) 
although a significant proportion of β-LPH is additionally processed to generate γ-LPH 
and β-endorphin(1-26/27/31) (Figure 5).  High molecular weight isoforms of ACTH exist 
following glycosylation in some species, such as mouse (Mains et al., 1977) and rat 
(Mains and Eipper, 1980).  Such corticotrope-like processing mechanisms are also 
observed in extra-pituitary tissues like the immune system (Lyons and Blalock, 1997) and 
the placenta (Raffin-Sanson et al., 2003; Bicknell, 2008).  However, POMC maturation 
in the placenta is unorthodox and distinct as fully processed peptides are also produced, 
such is the case in melanotropic cells (Raffin-Sanson et al., 2003; Bicknell, 2008). 
In intermediate pituitary melanotrope cells, PC2 either working alone or 
synergistically with PC1/3 results in more extensive processing of POMC (Figure 5).  
This maturation process also occurs in non-endocrine POMC-expressing tissues such as 
the skin (Bicknell, 2008; Rousseau et al., 2007) as well as the caudal medulla (Dores et 
al., 1986) and hypothalamus (Bicknell, 2008; Seidah et al., 1999) of the brain.  
Consequently, all eight dibasic sites as well as the tetrabasic site are cleaved in a temporal 
manner, liberating a more diverse repertoire of peptide products.  For example, γ-MSH is 
derived from the N-terminal region, pro-γ-MSH, while γ-LPH is cleaved further to 





Figure 5.  Prototypical tissue-specific processing pattern of POMC in the anterior and 
intermediate pituitaries or lobes.  Major end-products in the anterior pituitaries include 
the N-terminal POMC fragment (pro-γ-MSH), ACTH and β-endorphin.  In the 
intermediate pituitary, the N-terminal fragment and ACTH are further processed into γ3-
MSH and α-MSH, respectively.  Furthermore, β-MSH is liberated from γ-LPH in the 
intermediate pituitaries.  In anuran amphibians, intermediate pituitary β-endorphin can be 





a smaller β-endorphin(1-8) fragment is also excised from full length β-endorphin 
following cleavage at a monobasic arginine site; however, truncated forms of β-
endorphin represents minor end-products in other vertebrates including mammals (Dores 
et al., 1994).  Likewise in the intermediate lobe melanotropes, ACTH is further cleaved at 
the tetrabasic site to yield corticotropin-like intermediate peptide (CLIP or ACTH(18-39)) 
and α-MSH as major end-products. 
Following endoproteolytic cleavage in the secretory pathway by the specific PCs, 
removal of the remaining basic residues is accomplished by carboxypeptidase E (CPE).  
For α-MSH, this event precedes the C-terminal amidation by peptidylglycine α-amidating 
monooxygenase (PAM) (Figure 6).  Like pituitary melanotrope-derived β-endorphin, α-
MSH also undergoes N-acetylation via the action of N-acetyltransferase.  However, a 
dichotomy exists in the N-acetylation mechanism of α-MSH and β-endorphin isoforms 
between mammals and amphibians.  Specifically, N-acetylation of amphibian α-MSH 
00occurs immediately following exocytotic release in contrast to β-endorphin, which is 
N-acetylated during intracellular trafficking as observed in the frog, Xenopus laevis 
(Figure 7) (Dores et al., 1991, 1993b).  The latter mechanism is analogous to the N-
acetylation mechanisms of mammalian α-MSH and β-endorphin.  In addition, α-MSH 
derived from anuran amphibians can only be monoacetylated at the N-terminal alanine 
residue.  Mammalian α-MSH, on the other hand, can undergo both N-monoacetyl- and 
N,O-diacetylation at the N-terminal serine.  Consequently, the various isoforms of 
POMC-derived peptides produced can be attributed to the tissue-specific PC-mediated 





Figure 6.  Schematic of the posttranslational processing of POMC to generate α-MSH 
within mammalian intermediate pituitaries.  Key endoproteolytic cleavage steps 
involving PC1/3 and PC2 are indicated.  Subsequent to PC2-mediated cleavage, 
carboxypeptidase E removes residual basic residues prior to C-terminal amidation by the 
amidating enzyme, PAM.  The acetylation of the N-terminal serine residue in mammals 
(or alanine residue in amphibians) to produce acetylated forms of α-MSH is also 






Figure 7.  Comparison of mammalian and amphibian N-acetylation mechanisms of 
ACTH(1-13)NH2 and β-endorphin in the intermediate pituitary.  Posttranslational 
endoproteolytic processing events are also illustrated.  In both mammals and amphibians, 
β-endorphin is N-acetylated intracellularly prior to secretion as is the case with 
mammalian ACTH(1-13)NH2 (desacetyl-α-MSH), which undergoes N- and N,O-
acetylation to produce monoacetyl- and diacetyl-α-MSH at the N-terminal Ser, 
respectively.  In amphibians, ACTH(1-13)NH2 (desacetyl-α-MSH) is modified to 
produce N-acetyl-ACTH(1-13)NH2 (α-MSH) at the N-terminal Ala only following 






Enzymatic Basis of POMC Processing 
 The activities of PC1/3 and/or PC2 are instrumental in facilitating the differential 
endoproteolytic cleavage mechanisms of POMC.  Both endoproteases belong to the 
larger family of evolutionarily-conserved subtilisin-like prohormone or proprotein 
convertases (PCs) (Rockwell et al., 2002; Seidah and Chrétien, 1999).  Other members of 
this family include furin (also called paired amino acid cleavage enzyme or PACE), 
PACE4, PC4, PC5/6, PC7/8 and SKI-1 (subtilision-kexin-isozyme-1) (Seidah and 
Chrétien, 1999; Seidah et al., 1999).  With the exception of SKI-1, which cleaves 
preferentially C-terminal of hydrophobic leucine and threonine residues, all other 
subtilisin-like members cleave C-terminal of basic residues (Seidah and Chrétien, 1999; 
Seidah et al., 1999).  As calcium-dependent serine endoproteases, the PCs process a 
diverse repertoire of inactive precursors into biologically active molecules such as 
peptide hormones, transcription factors, enzymes, adhesion molecules, cell surface 
receptors and surface glycoproteins of pathogenic viruses and bacteria (Rockwell et al., 
2002; Seidah and Chrétien, 1999; Seidah et al., 1999). 
A feature shared by all PC members is the high degree of homology to both 
bacterial subtilisins and yeast kexin, which suggests descent from a common ancestral 
gene (Seidah and Chrétien, 1999).  The structural composition of the PC members 
consists of the N-terminal signal peptide domain for intracellular trafficking, the pro-
segment domain with intramolecular chaperone function, the catalytic domain that 





Figure 8.  Representation of the various mammalian subtilisin-like family members in 
relation to bacterial subtilisin and yeast kexin.  Major domains to note include the 
conserved N-terminal signal peptide, the pro-segment domain, the catalytic domain, the 
RDG motif-containing P domain.  Less conserved are the characteristic C-terminal 
regions of each enzyme.  Transmembrane and cytoplasmic domains are also indicated 
along with Cys-rich regions and potential N-glycosylation sites.  Endoproteolytic 




stability (Figure 8) (Seidah and Chrétien, 1999).  These conserved functional N-terminal 
domains are found in all PC family members while the C-terminal regions are unique.  In 
fact, mammalian subtilase family members were initially discovered through a sequence 
homology analysis of kexin, a yeast endoprotease (Bergeron et al., 2000).  PC family 
homologs have subsequently been revealed in other species and their tissue distributions 
and physiological roles have been extensively characterized. 
 Because PC members are able to cleave POMC and other propeptides 
indiscriminantly in vitro, it was postulated that PC activity was spatially regulated 
through both specific tissue and cellular distributions.  For example, both furin and PC7/8 
function exclusively in the Golgi apparatus and constitutive secretory pathway, while 
PC5/6 and PACE4 mediate cleavage at the cell surface thereby ruling out their role in 
processing POMC (Rholam and Fahy, 2009).  Additionally, the testicular and ovarian 
germ cell expression of PC4 (Henrich et al., 2005; Seidah and Chrétien, 1999) precludes 
its role in the maturation of POMC.  Initial analysis has shown that POMC is not a SKI-1 
substrate despite the coexpression of this enzyme in the anterior pituitary (Seidah et al., 
1999).  Of all the subtilisin-like family members, only PC1/3 and PC2 have been 
demonstrated to process POMC as a natural substrate.  Both PC1/3 and PC2 are localized 
in dense core vesicles of the regulated secretory pathway of both endocrine and non-
endocrine POMC-expressing tissues (Seidah and Chrétien, 1999; Seidah et al., 1999).  
This is in agreement with colocalization studies of PC1/3 ((Tanaka et al., 1997) and PC2 




POMC observed in gene-knockout PC1/3- (Zhu et al., 2002) and PC2-null (Laurent et al., 
2004) mice models betokens their vital role in precursor cleavage. 
Like POMC, both PC1/3 and PC2 are initially synthesized as inactive precursors 
or zymogens (proPCs) that are proteolytically activated at several multibasic sites (Lee et 
al., 2004; Muller et al., 2000).  Subsequent to the removal of the ER-targeting signal 
peptide, the zymogen proPC1/3 is activated through two sequential autocatalytic events 
in the regulated secretory pathway (Figure 9A).  The first occurs at the level of the ER 
and results in the removal of the N-terminal pro-segment, which exhibits inhibitory 
effects, to generate a partially active 84 kDa form.  This step is critical for the subsequent 
sorting of the enzyme into the trans golgi network (TGN) where the second autocatalytic 
event produces the more active, although less stable, 66 kDa species that is stored in the 
secretory granules (Seidah et al., 1999; Rockwell et al., 2002; Zhou and Lindberg, 1993).  
A pH optimum of pH 5-7 suggests that PC1/3 can conceivably function in both the TGN 
and secretory granules (Rockwell et al., 2002).  Unlike proPC1/3 and the other subtilisin-
like family members, proPC2 is activated to its 68-kDa form much later in the secretory 
pathway at the TGN and immature secretory granules (ISG) following autocatalytic 
excision of the pro-segment (Seidah et al., 1999) (Figure 9B).  The narrow pH optimal of 
5 for PC2 is consistent with its delayed activation (Rockwell et al., 2002).  Nonetheless, 
in each scenario, the excised pro-segment acts as a competitive inhibitor until its release 
following cleavage at the correct pH and/or calcium optimum (Bergeron et al., 2000) 






Figure 9.  Schematic representation of the maturation process of PC1/3 and PC2 along 
various compartments of the secretory pathway.  Structural domains of each respective 
PC are indicated.  Key autocatalytic cleavage steps as well as interactions with accessory 








appears to be regulated intramolecularly by both the N- and C-terminals but that of PC2 
only by the N-terminal. 
Of the subtilisin-like family members, only proPC2 is also known to associate 
with a specific neuroendocrine binding protein or chaperone called 7B2 (Figure 9B) 
(Rockwell et al., 2002; Seidah et al., 1999), which itself is produced as a precursor (pro-
7B2) and activated following cleavage by a furin-like enzyme in the TGN (Seidah et al., 
1999).  Initial interaction of proPC2 with 7B2 is inhibitory due to the inhibitory basic 
motif-containing C-terminal region; however, 7B2 binding is absolutely necessary for 
PC2 maturation as the N-terminal domain expedites PC2 exit from the ER and drastically 
improves zymogen activation late in the secretor pathway (Rockwell et al., 2002; Seidah 
and Chrétien, 1999; Seidah et al., 1999).  On the other hand, the intermolecular 
interaction of PC1/3 with proSAAS, a granin-like secretory protein (Lee et al., 2004), is 
strictly inhibitory.  This inhibition is relieved only following endoproteolysis at the 
proSAAS central furin cleavage site.  In essence, interactions of 7B2 and proSAAS with 
their respective PCs might represent a temporal regulation of endoprotease function. 
The catalytic triad in both PC1/3 and PC2 consists of conserved Ser, His and Asp 
active site residues, which is a defining feature of serine proteases.  The active site of 
PC1/3 also contains Asn, which stabilizes formation of the oxyanion hole during 
hydrolysis of the scissile bond (Rockwell et al., 2002).  However, this Asn residue is 
replaced by Asp in PC2, which has been suggested to play a role in the slow activation of 




each enzyme is also thought to interact with the basic residues of the substrate.  Because 
PC2 contains the fewest number of acidic amino acid residues in the vicinity of the 
binding pocket, it is presumed that PC2 will have the least stringent requirement for 
additional basic residues at the endoproteolytic cleavage site (Rockwell et al., 2002). 
Two major although not mutually exclusive hypotheses have been proposed with 
respect to the mechanism by which endoproteolytic cleavage enzymes recognize a 
substrate cleavage site in a neuropeptide precursor.  The first proposes that the minimal 
substrate recognition motif for proteolytic cleavage by the PCs is (R/K)-(X)n-(R/K)↓ 
where n = 0, 2, 4 or 6 and X is any amino acid except Cys or Pro (Seidah and Chrétien, 
1999).  Evidence also suggests that privileged secondary structures in or around the 
vicinity of the cleavage site also heavily influences processing (Rholam and Fahy, 2009).  
However, neither hypothesis explains the cleavage hierarchy at dibasic sites which 
preferentially occurs in the order KR > RR > RK > KK (Rholam and Fahy, 2009; 
Thomas et al., 1991). 
Overview and Objectives of Project 
To this end, the molecular basis for the differential recognition of proteolytic 
processing sites by specific endoproteases remains an area of further investigation.  The 
project examined the PC recognition motif of (R/K)-(X)n-(R/K)↓ where n = 0, 2, 4 or 6 
and X is any amino acid except Cys or Pro (Seidah and Chrétien, 1999).  Specifically, 










Table 1.  Amino acid residues in the vicinity of prohormone cleavage sites.  
Shown are a few prohormones that are known to undergo maturation by the PC family.  
Critical amino acids are shown in bold and cleavage is indicated to take place C-terminal 




correspondingly numbered as 1, 2, 3, etc.  In other words, cleavage C-terminal of the 
R
142
↓ residue can occur if a basic amino acid is present at positions 0, 2, 4 or 6. 
An examination of mammalian POMC sequences reveals the presence of at least 
one basic residue at these positions (Table 1), thereby reinforcing this hypothesis.  
However, an inspection of the anuran amphibian S. tropicalis POMC sequence reveals 




 monobasic cleavage sites.  
In fact, this is also the case for several other species whereby cleavage sites are not 
preceded by N-terminal basic residues (Dores et al., 2002).  Taken together, two 
hypotheses can be formulated based on these observations.  The first hypothesis 
postulates that at a KR dibasic cleavage site, the R residue is essential for endoproteolysis.  
The second hypothesis proposes that basic residues N-terminal of the cleavage R(↓) are 
not essential for cleavage to occur.  For this reason, Silurana tropicalis POMC was 
selected as a model prohormone for the structure-function analysis of endoproteolysis at 
dibasic sites.  Specifically, the absolute requirement of basic residues for cleavage by 
PC2 in and around the vicinity of the KR↓ cleavage site between joining peptide (JP) and 
the α-MSH/ACTH segment will be examined. 
Experimental Design of Project 
The project tested each of these hypotheses through a combination of POMC 
mutants (Figure 10) and population cell line studies followed by biochemical, 
immunocytochemical and molecular biology analysis methods.  To test the first 




R137A mutants helped address the second hypothesis.  For transient transfections of a 
population of cells, the mouse (Mus musculus) pancreatic α-cell line, αTC1 clone 9 
(αTC1.9), was selected.  This terminally differentiated cell line is derived from the 
parental αTC1 cell line that was created from an adenoma produced in transgenic mice 
expressing the SV40 virus large T antigen under control by the rat preproglucagon 
promoter.  A study by Ugleholdt et al. (2006) demonstrated that this cell line expressed 
predominantly PC2 and negligible PC1/3, which makes it appropriate for this study.  
Additionally, this cell line expresses endogenous proglucagon; consequently, the αTC1.9 
cell line represents an ideal model system for the study of posttranslational processing 
mechanisms. 
Because cleavage of wild-type POMC in the αTC1.9 cell line is predicted to 
follow an intermediate pituitary pattern, the steady-state processing of endogenous 
POMC in S. tropicalis intermediate pituitary will be analyzed first.  Biochemical analysis 
will employ radioimmunoassays (RIAs) following gel filtration chromatography 
fractionation of protein content extracted from the frog pituitaries and the transfected cell 
line.  Additionally, immunoreactive forms of α-MSH and N-acetyl-β-endorphin forms 
will be analyzed by reversed-phase high performance liquid chromatography (HPLC) to 
determine the extent of posttranslational modifications.  The αTC1.9 cells will be 
transfected with either wild-type or mutant frog POMC constructs and transfection 
efficiency will be determined immunocytochemically.  Likewise, the steady-state levels 
of exogenous wild-type and mutant S. tropicalis POMC processing and posttranslational 





Figure 10. S. tropicalis POMC sequence.  Nucleotide and polypeptide sequences are 
indicated in conjunction with melanocortin (red) and opioid (blue) core sequences.  Basic 
amino acid residues with their corresponding codon sequences highlighted in green 
(residues 137, 141 and 142) were selected for site-directed mutagenesis via alanine 
substitutions.  The bold underlined sequence spanning residues 104-154 correspond to the 





described above.  Additionally, the relative expression levels of exogenous S. tropicalis 
POMC and endogenous glucagon, PC1/3 and PC2 in the αTC1.9 cell line will be 







MATERIALS AND METHODS 
Animal Tissue Extractions 
Mature female tropical (western) clawed frogs, Silurana tropicalis (formerly 
Xenopus tropicalis), were purchased from Nasco (Fort Atkinson, Wisconsin, USA) and 
maintained in aquaria at 22ºC.  The animals were fed weekly with Xenopus Adult Food 
(Carolina, Burlington, NC, USA).  The snout-vent length (SVL) of the animals ranged 
from 40 to 55 mm and averaged 48.8 ± 1.15 mm (standard error of the mean, SEM; n = 
10).  The animals were anesthetized by immersion in MS222 (Sigma-Aldrich, St. Louis, 
MO, USA) prior to sacrifice by decapitation.  Brain and pituitary tissues were dissected 
separately.  The latter were further separated into anterior (pars distali) and intermediate 
(pars intermedia) pituitaries.  During the sacrifice process, all surgically extracted tissues 
were quick frozen on dry ice followed by storage at -80ºC. 
Poly(A) mRNA Extraction and First-Strand cDNA Synthesis 
 Poly(A) mRNA was extracted following protocols established by the 
Dynabeads® mRNA DIRECT
TM
 Kit (Invitrogen, Carlsbad, CA, USA).  Specifically, 50 
mg of brain tissue obtained from five animals was homogenized using 1.0 mm diameter 
glass beads (BioSpec Products, Bartlesville, OK, USA) in conjunction with the 
FastPrep
TM 




MA, USA).  The reverse transcription reaction consisted of 1 µl oligo(dT)20 (500 ng), 50 
ng mRNA and 1 µl of 10 mM dNTP with double-distilled water to a final volume of 13 
µl.  The mix was heated at 65ºC for 5 minutes and chilled on ice for 1 minute prior to 
addition of 4 µl of 5X First-Strand Buffer, 1 µl of 0.1 M DTT, 40 U RNaseOUT
TM
 
Recombinant RNase Inhibitor and 200 U SuperScript
TM
 III reverse transcriptase (RT).  
The 20 µl reaction was incubated at 50ºC for 45 minute and subsequently inactivated at 
70ºC for 15 minutes.  Finally, the reaction was incubated with 2 U E. coli RNase H at 
37ºC for 20 minutes to remove complementary RNA. 
Cloning of Target Gene 
 Sense (5’- CTG AAA TCA ACA GCC TCC AGT CCT -3’) and antisense (5’- 
ATC TGT ATG GAG CTC TGG GTG CAA -3’) primers were designed to be 
complementary to the 5’ and 3’ untranslated regions (UTR) of the S. tropicalis 
proopiomelanocortin (POMC) cDNA coding sequence as determined from the “Xenopus 
tropicalis” genome project from Xenbase 
<http://www.xenbase.org/gene/showgene.do?method=display&geneId=XB-GENE-
483702>.  Optimized PCR reactions consisted of 2 µl buffer B12 (100 mM Tris pH 9.2, 
750 mM KCl, 35 mM MgCl2), 2 µl each of 10 µM sense and 10 µM antisense primers, 2 
µl of 2 mM NTP, 1 unit Recombinant Taq DNA polymerase (Invitrogen, Carlsbad, CA, 
USA), 0.76 µg of S. tropicalis cDNA template and double-distilled water to a total 
reaction volume of 20 µl.  All reagents were mixed on ice prior to running on a PTC-200 




included an initial denaturation step at 94ºC for 3 minutes followed by 33 repetitive 
cycles of amplification.  Each cycle consisted of denaturation at 94ºC for 45 seconds, 
annealing at 65.2ºC for 30 seconds and extension at 72ºC for 1 minute and 30 seconds 
with a final extension step at 72ºC for 10 minutes.  DNA was stored at 4ºC until later use. 
Gel Electrophoresis, Gel Purification and Subcloning 
  PCR products were resolved by gel electrophoresis on a 1% agarose gel 
containing 0.1 µg/ml ethidium bromide in 1X TAE buffer (0.04 M Tris-acetate, 0.001 M 
EDTA (pH 8.0)) alongside an exACTGene Low Range Plus DNA Ladder (Fisher 
Scientific, Pittsburgh, PA, USA).  The gel ran for approximately 30-35 minutes at 110 
mV and was visualized by means of the Gel Doc
TM 
XR UV Documentation System (Bio-
Rad, Hercules, CA, USA).  Gel images were acquired using the Quantity One® 1-D 
Image Analysis Software, Version 4.6.1 (Bio-Rad, Hercules, CA).  Bands corresponding 
to the expected PCR product size of 858 base pairs were excised with a sterile blade, gel-
purified using Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI, 
USA) and subcloned into the pTARGET
TM
 Mammalian Expression Vector System 
(Promega, Madison, WI, USA).  The ligation reaction consisted of 2 µl of PCR product 
with 1 µl of T4 DNA ligase (10X) buffer, 1 µl of pTARGET
TM
 vector (60 ng), 1 µl of T4 
DNA ligase (3 U/µl) and 7 µl of double-distilled water to a final volume of 10 µl. 
Transformation and Screening 
 Z-competent
TM
 Escherichia coli DH5α cells (Zymo Research, Orange, CA, USA) 




with 100-200 ng of ligation products and incubated on ice for 2 minutes.  The cells were 
subsequently plated onto LB agar ampicillin (100 µg/ml) for selection of transformants.  
The plates were additionally top-streaked with 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) to detect successful ligations, as used in blue-white selection.  
Transformants were streaked to obtain individual colonies for purification of vector.  All 
plates were incubated overnight at 37ºC.  Subsequent transformations for vector 
propagation used 100 ng of miniprep or maxiprep DNA. 
Vector Purification 
 Single colonies were inoculated into LB broth containing ampicillin (100 µg/ml) 
and grown overnight at 37ºC on a shaking platform at 200 rpm.  The volumes of LB 
broth ampicillin used were either 2 ml for mini-prep or 100 ml for maxi-prep isolation of 
vector DNA.  Miniprep and maxiprep DNA were obtained following the manufacturer’s 
protocols for the Zyppy
TM
 Plasmid Miniprep Kit (Zymo Research, Orange, CA, USA) 
and the EndoFree ® Plasmid Maxi Kit (Qiagen, Valencia, CA, USA), respectively. 
Vector-Specific Primers and Insert Sequence Verification 
 To verify the sequence of the cloned insert, the T7 promoter primer (5’- TAA 
TAC GAC TCA CTA TAG CG -3’) and the pTARGET
TM
 sequencing primer (5’- TTA 
CGC CAA GTT ATT TAG GTG ACA -3’) (Promega, Madison, WI, USA) were used to 
sequence upstream (sense reaction) and downstream (antisense reaction) of the multiple 
cloning site, respectively.  Samples for sequencing were prepared using the CEQ DCTS 




specifications.  Briefly, 1 µl of either 10 µM sense or antisense primer (1 µM) was 
separately combined with 4 µl of DCTS Quick Start Master Mix, 0.2-0.6 µg of the vector 
template and double-distilled water to a final reaction volume of 10 µl.  To enhance the 
reaction, samples were denatured at 96ºC for 1 minute prior to amplification using a 
PTC-200 Peltier Thermal Cycler (MJ Research, St. Bruno, QC, Canada).  The thermal 
profile consisted of denaturation at 96ºC for 20 seconds, annealing at 50ºC for 20 seconds 
and extension at 60ºC for 4 minutes for a total of 30 cycles.  Labeled DNA was then 
ethanol-precipitated beginning with the addition of 0.5 volume of salt solution (1.2 M 
sodium acetate, 40 mM EDTA and 20% glycogen) and 6X volume of ice-chilled 95% 
ethanol.  Following 15 minutes of centrifugation at >8500 x g, the supernatant was 
aspirated.  The crude DNA pellet was then washed in 200 µl 70% ethanol and centrifuged 
for an additional 5 minutes at >8500 x g.  The supernatant was subsequently aspirated 
and the pellet was air-dried for 15 minutes prior to resuspension in 40 µl formamide.  
Automated sequencing was achieved on 96-well plate format using the CEQ 2000 DNA 
Sequencer (Beckman-Coulter, Fullerton, CA, USA).  Sequence data were analyzed using 
Chromas and NCBI BLAST. 
Site-directed Mutagenesis 
 Wild-type S. tropicalis POMC-pTARGET
TM
 construct (15 µg) was sent to 
Retrogen (San Diego, CA, USA) for site-directed mutagenesis.  The missense mutants 




(Figure 10).  The constructs were propagated and purified as previously described.  
Sequence data provided by Retrogen were analyzed as described above. 
Cell Culture, Media and Subculturing 
 The mouse pancreatic α-cell line, αTC1 clone 9 (αTC1.9), was purchased from 
the American Type Culture Collection (ATCC, Manassas, VA, USA) at a passage 
number of 35, according to the ATCC product information sheet.  Initial transfection 
experiments involved αTC1.9 cells, post-thaw passage number 5, that were kindly 
provided by Dr. Joe K. Angleson (University of Denver, Denver, CO, USA).  Cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4 mM L-
glutamine and 16 mM glucose.  Medium was further supplemented with 44 mM sodium 
bicarbonate, 10% heat-inactivated fetal bovine serum (FBS), 15 mM HEPES, 1% 100x 
MEM (Nonessential amino acids) and 0.02% bovine serum albumin (BSA), fraction V.  
Additionally, medium was augmented with 100 U/ml Penicillin and 100 mg/ml 
Streptomycin (Invitrogen, Carlsbad, CA, USA) as well as 100 μg/ml Normocin
TM
 
(InvivoGen, San Diego, CA, USA) for protection against bacterial, fungal and 
mycoplasmal contamination. 
Media renewal took place 2-3 times weekly and cells were grown at 37ºC in 5% 
CO2-95% air with a relative humidity of 70-90%.  When cells reached 70-80% 
confluency, subcultures were prepared.  Specifically, medium was aspirated and cells 
were briefly washed in 1X PBS to remove residual media.  Next, 1 ml of trypsin EDTA 
1X (Mediatech, Manassas, VA, USA) was added per 25 cm
2






followed by 3-5 minutes incubation at 37ºC  to dissociate cells.  Then 3 ml of media was 
added per 25 cm
2
 flask (9 ml per 75 cm
2
 flask) in order to inactivate the proteolytic 
enzyme, trypsin.  Cells were then pelleted by briefly spinning at 100-200 x g for 5-10 
minutes and then resuspended in fresh media.  The cells were subsequently dispersed at a 
subcultivation ratio of 1:2, 1:3 or 1:4. 
Transfection 
 Transient transfections of the αTC1.9 cell line were achieved through 
nucleofection using the Nucleofector® II Device (Lonza, Walkersville, MD, USA).  This 
technology, through a combination of electrical parameters and cell-specific reagents, 
enables efficient transfer of nucleic acids directly into the cell nucleus.  The standard 
nucleation reaction employed program T-020 and consisted of 1.5-2 x 10
6
 cells 
resuspended in 100 µl solution L together with 2 µg of vector substrate.  The cells were 






onto poly-L-lysine-coated 6-well 
plates (10 cm
2
 per well) or 2-well chamber slides (4 cm
2
 per well) following 10 minutes 
recovery at 37 ºC in 500 µl media.  Typically, the contents of one reaction were plated for 
immunocytochemical analysis while the cells harvested from five or six reactions 
constituted one replicate for biochemical analysis. 
Immunocytochemistry 
 At 48 hours post-nucleofection, the αTC1.9 cells cultured on poly-L-lysine-coated 
chamber slides were fixed with prewarmed 4% paraformaldehyde in 1X phosphate 




Triton-X for 10 minutes prior to 1 hour incubation at 37ºC with the primary antibody, 
guinea pig anti-rat POMC antiserum (1:500, National Hormone and Peptide Program, 
Torrance, CA, USA).  Cells were next stained with the secondary antibody, donkey anti-
guinea pig antiserum conjugated to Cy3 (1:800), acquired from Jackson 
ImmunoResearch Laboratories (West Grove, PA, USA).  All antiserum were diluted in 1% 
BSA in 1X PBS prior to use.  Intermittent wash steps comprised of rinsing with 1X PBS 
three times.  Following 30 minutes incubation at room temperature, the cells were 
mounted in Vectashield® with DAPI (Vector Laboratories, Burlingame, CA, USA).  
Images were viewed under oil immersion at 100X on the Axioplan-2 fluorescence 
microscope (Zeiss, Ostalbkreis, Baden-Württemberg, Germany) using the SlideBook 
imaging software version 3.05 (Intelligent Imaging, Denver, CO, USA).  The mean 
transfection efficiency was 72 ± 4% SEM corresponding to the proportion of Cy3-
positive cells displaying a cytoplasmic punctuate staining pattern. 
Protein Extraction 
 At 48 hours post-nucleofection, the αTC1.9 cells were harvested from 6-well 
plates through trypsinization and centrifugation as previously described.  Typically 1-4 x 
10
6 
cells were harvested per replicate for protein extraction.  Cells were extracted in 5 N 
acetic acid containing 2 mM phenyl methyl sulfonyl fluoride (PMSF) (Sigma-Aldrich, St. 
Louis, MO, USA).  S. tropicalis pars distali and pars intermedia, dissected as described 
earlier, were separately extracted in a similar manner.  All samples were mechanically 




probe (Wheaton, Millville, NJ, USA) and subsequently concentrated under vacuum with 
centrifugation at 10,000 x g at 4ºC (Speed Vac and Refrigerated Condensation Trap, 
Savant, Farmingdale, NY, USA). 
Gel Filtration Chromatography 
 Concentrated acid extracts were individually fractionated by gel filtration 
chromatography on a Sephadex G-50 (medium) (Sigma-Aldrich, St. Louis, MO, USA) 
column (1 x 40 cm) (GE Healthcare Life Sciences, Pittsburgh, PA, USA) equilibrated in 
10% formic acid.  Prior to fractionation, all samples were supplemented with 2 mg/ml 
BSA and 15% 2-mercaptoethanol for marking of void (Vo) and total volumes (Vt), 
respectively.  Both internal markers were detectable spectrophotometrically at A280.  The 
column flow rate was 10 ml/hr and 400 µl-sized fractions were collected by an automated 
fraction collector. 
Iodination and Radioimmunoassay (RIA) Procedures 
 Peptides were iodinated with iodine-125 (
125
I) (Perkin-Elmer, Waltham, MA, 
USA) by the chloramine-T (N-chloro p-Toluenesulfonamide) procedure and radiolabeling 
reactions were terminated by addition of sodium metabisulfite.  Radiolabeled peptides 
were separated from free iodine by gel filtration on a Sephadex G-10 column (1 x 10 cm) 
(Sigma-Aldrich, St. Louis, MO, USA) equilibrated in 5% acetic acid.  Synthetic 
standards included human β-endorphin(1-31), N-acetylated salmon β-endorphin II, 
synthetic mammalian α-MSH (all purchased from Bachem, Torrance, CA, USA) and 




Aliquots of column fractions were dried under vacuum as described earlier and 
separately analyzed with a series of heterologous radioimmunoassays (RIAs).  Assays 
were carried out in 0.2 ml of 150 mM sodium phosphate buffer containing 0.1% BSA 
(pH 7.5).  The reactions were incubated for 16-24 hours at 4ºC and terminated by 
incubation in 2.5X volume each of rabbit carrier and precipitating reagent (both 
purchased from Millipore, Billerica, MA, USA) for 1 hour at 4ºC.  Total quantities of 
detectable immunoreactive peptides are expressed as the mean pmol ± SEM per tissue or 
10
6
 transfected cells.  In the latter scenario, the mean pmol content of each POMC-
derived immunoreactive form was calculated per 10
6
 nucleofected cells adjusted for the 
proportion of Cy3-positive cells, which was 71.75% ± 3.84% SEM, as reported earlier. 
C-terminal-specific α-MSH RIA:  Antiserum 7A was raised by Hazelton Research 
Products (Denver, PA, USA) by injecting rabbits with synthetic ACTH(1-13)NH2 
conjugated to BSA.  This antiserum recognizes the C-terminal amide and was used at a 
final dilution of 1:15,000.  Antiserum 7a exhibits full molar cross-reactivity with 
ACTH(1-13)NH2 and α-MSH but not α-MSH free acid. 
C-terminal-specific β-endorphin RIA:  Antiserum 2 was raised by Hazelton Research 
Products (Denver, PA, USA) by injecting rabbits with human β-endorphin(1-31) 
conjugated to BSA.  Specificity tests demonstrated that this antiserum fully recognizes 
human β-endorphin(1-31) and β-endorphin(1-26) but not human α-endorphin(1-16) or 
salmon β-endorphin I.  This antiserum also recognizes β-LPH as well as full-length 




N-acetyl-specific β-endorphin RIA:  The N-acetyl-specific beta-endorphin antiserum was 
raised by Hazelton Research Products (Denver, PA, USA) by injecting rabbits with 
synthetic N-acetylated salmon β-endorphin(1-16) conjugated to BSA and is directed 
against the acetylated N-terminal.  This antiserum fully cross-reacts with N-acetylated 
forms of β-endorphin and was used at a final dilution of 1:20,000. 
Midregion-specific ACTH RIA:  Antiserum 19 was raised by Hazelton Research Products 
(Denver, PA, USA) by injecting rabbits with synthetic human ACTH(1-24) conjugated to 
BSA.  This antiserum was used at a final dilution of 1:20,000.  Specificity tests 
demonstrated that this antiserum recognizes residues 18-24 and can cross-react with 
ACTH biosynthetic intermediates and POMC (Dores et al., 1986).  This antiserum fully 
recognizes human ACTH(1-39), ACTH(1-24) and ACTH(18-39) (CLIP) but not α-MSH. 
Reversed-Phase High Performance Liquid Chromatography (HPLC) 
 The peak of α-MSH and N-acetyl-β-endorphin(1-8) immunoreactivity detected by 
RIAs following gel filtration was pooled, was dried under vacuum in the presence of 5% 
2-mercaptoethanol and redissolved in 0.2 ml of 0.1% trifluoroacetic acid (Buffer A) for 
further analysis by reversed-phase HPLC on a C-18 ODS ultrasphere 5 µm column (4.6 
mm x 25 cm, Beckman-Coulter, Fullerton, CA, USA).  The column was equilibrated in 
0.1% trifluoroacetic acid (Buffer A) and eluted with a nonlinear 0.1% trifluoroacetic 
acid/acetonitrile gradient (Buffer B) (5% Buffer B from 0-5 min, 5-30% Buffer B from 5-
10 min, 30-40% Buffer B from 10-40 min, 40-80% Buffer B from 40-45 min, 80% 




The column flow rate was 60 ml/hour and 0.5 ml-sized fractions were collected at 0.5 
minute intervals.  Aliquots of column fractions were dried under vacuum and screened by 
the C-terminal α-MSH and the N-terminal β-endorphin RIAs.  The elution profile of the 
immunoreactive form of wild-type α-MSH was compared to synthetic frog ACTH(1-
13)NH2 (desacetyl-α-MSH) and frog N-acetyl- ACTH(1-13)NH2 (α-MSH) (all purchased 
from New England Peptides, Gardner, MA, USA).  Likewise, the elution profile of the 
immunoreactive N-acetyl-β-endorphin(1-8) was compared to synthetic Xenopus N-
acetylated β-endorphin(1-8) (Bachem, Torrance, CA, USA).  The synthetic standards 
were chromatographed separately and detected spectrophotometrically at A220. 
Quantitative Real-Time PCR (QRT-PCR) 
 Total RNA was extracted from αTC1.9 cells using the RNAqueous®-4PCR Kit 
(Ambion, Austin, TX, USA) according to the manufacturer’s specifications.  To ensure 
the complete removal of genomic DNA, a more rigorous DNase I treatment involving a 
total of 2 µl of DNase 1 per 100 µl of total RNA-containing elution solution was 
employed for total RNA extraction from nucleofected cells.  This was applied 
sequentially as 1 µl of DNase 1 in conjunction with 0.1 volume of 10X DNase 1 buffer at 
half hour intervals for 1 hour.  The volume of the DNase Inactivation Reagent was 
adjusted accordingly from 0.1 to 0.2 volume.  Typical starting material ranged from 1-2 x 
10
6
 cells per extraction (the number of cells employed in one nucleofection reaction).  
The concentration and purity of the extracted total RNA were determined by UV 
spectroscopy at A260 and A260/280, respectively, on a NanoDrop
TM




Spectrophotometer (Thermo Scientific, Wilmington, DE, USA).  Using oligo(dT)20, 200 




 assays for M. musculus proglucagon, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), Pcsk1 (PC1/3), Pcsk2 (PC2) and a custom 
TaqMan
®
 assay for S. tropicalis POMC were purchased from Applied Biosystems 
(Foster City, CA, USA).  The 20 µl reaction comprised of 0.5X volume TaqMan
® 
Gene 
Expression Master Mix, 0.05X volume 20X TaqMan
®
 GeneExpression Assay Mix (both 
purchased from Applied Biosystems, Foster City, CA, USA) and 90 ng cDNA.  All 
reactions were carried out using the Bio-Rad iQ™5 Real Time PCR System (Hercules, 
CA, USA).  The thermal profile included an initial hold at 95ºC for 10 minutes followed 
by 40 cycles of denaturation at 95ºC for 15 sec and annealing/extension at 60ºC for 1 min.  
The forward and reverse primers for the custom S. tropicalis TaqMan
® 
assay were 5’-
CGCTCAAGGCGACAACATG-3’ and 5’-CCTTAATGGGCCTCCTCTTTCTC-3’, 
respectively.  The S. tropicalis POMC probe, 5’-CCAACGGGTTTCCCC-3’, was 
conjugated to the 5’-FAM reporter dye and the 3’-nonfluorescent quencher.  Primer and 
probe sequences for the inventoried TaqMan
® 
assays are proprietary and not available. 
Each Taqman assay was done in triplicates and the results are expressed as the 
normalized fold expression ± the standard deviation (SD) with GAPDH assigned as the 
reference gene.  All figures were created in the Bio-Rad Rad iQ™5 Real Time PCR 




Secondary Structure Prediction 
Predictions for β-turns were achieved by submitting polypeptide sequences to the 
Server for β-turn Types Prediction, Bioinformatics Centre, Institute of Microbial 








Steady-state Analysis of Posttranslational Processing of POMC in S. tropicalis 
Intermediate Pituitary 
 
 The endogenous processing profile of POMC in S. tropicalis intermediate 
pituitaries was established prior to assessing the extent of cleavage in POMC-transfected 
αTC1.9 cells.  Separate pools of intermediate pituitaries dissected from two pools of eight 
and five mature female frogs were separately extracted and fractionated by gel filtration 
chromatography on a Sephadex G-50 column (Figure 11).  Aliquots of dried fraction 
columns from intermediate pituitary extracts revealed major peaks of immunoreactivity 
corresponding to several POMC-derived products.  Specifically, the C-terminal directed 
α-MSH RIA detected peaks of immunoreactivity at Kav values of 0.80 and 0.79 from the 
pool of eight (Figure 11A) and five (Figure 11B) frogs analyzed, respectively.  Such Kav 
values correspond to an apparent molecular weight of 1.5 kDa, suggesting the presence of 
α-MSH-sized material in the intermediate pituitaries of the animals.  Likewise, the major 
peaks of β-endorphin(1-27/31)-sized immunoreactivity were detected at Kav values of 
0.53 (Figure 11A) and 0.54 (Figure 11B) and had an apparent molecular weight of 3.5 
kDa.  On the other hand, the immunoreactive forms detected by the N-acetyl-specific β-
endorphin RIA peaked at Kav values of 0.84 (Figure 11A) and 0.79 (Figure 11B).  The 









Figure 11.  Sephadex G-50 (1 x 40 cm) chromatography: Steady-state levels of S. 
tropicalis intermediate pituitary POMC-derived peptides.  Acid extracts of (A) eight and 
(B) five frog intermediate pituitaries were separately fractionated and aliquots were 
screened by the C-terminal β-endorphin RIA ( ), C-terminal α-MSH RIA ( ) 
and the N-acetyl β-endorphin RIA ( ).  Specifically, 3.5 kDa β-endorphin(1-27/31)-
sized material (Kav = 0.53, 0.54), 1.5 kDa α-MSH-sized material (Kav = 0.8, 0.79) and 1 
kDa N-acetyl-β-endorphin(1-8)-sized material (Kav = 0.84, 0.79) were detected.  
Corresponding Kav values are indicated above the peaks of immunoreactivity.  Void (VO) 
and total (VT) volumes were marked by BSA and β-mercaptoethanol, respectively.  Both 









N-acetyl-β-endorphin(1-8)-sized products.  The latter Kav value, on the other hand, was 
slightly offset in the corresponding column run. 
Thus in the intermediate pituitaries of these animals, endogenous POMC was 
processed into β-endorphin(1-27/31)-sized products as well as the C-terminally truncated 
form, N-acetyl-β-endorphin(1-8).  However, only the latter was N-acetylated and 
appeared in the minority.  This is in contrast to that observed in the intermediate 
pituitaries of Bufo marinus (Steveson et al., 1990) and X. laevis (Dores et al., 1991) 
where low molecular weight N-acetylated immunoreactive forms predominate as major 
end-products.  The average content of α-MSH-sized immunoreactive form per 
intermediate pituitary was 4.62 ± 0.44 pmol (n = 2).  This was found to be in equimolar 
amounts with the β-endorphin(1-27/31)-sized and the N-acetyl-β-endorphin(1-8)-sized 
material, which averaged 3.56 ± 1.16 and 1.39 ± 0.216 pmol per intermediate pituitary (n 
= 2), respectively. 
Reversed-phase HPLC Analysis of S. tropicalis Intermediate Pituitary α-MSH-
related Material from Steady-state Analysis 
 
To further characterize the S. tropicalis intermediate pituitary α-MSH-sized 
species, corresponding column fractions were separately pooled and concentrated under 
vacuum for analysis by reversed-phase HPLC (Figure 12).  This process helped 
differentiate between forms of α-MSH that vary in the degree of N-acetylation, a 
posttranslational modification which cannot be resolved by gel filtration alone.  Analysis 







Figure 12.  Reversed-phase HPLC analysis: α-MSH-sized material from S. tropicalis 
intermediate pituitaries.  Aliquots from fractions corresponding to the α-MSH-sized 
material from the replicates of (A) eight and (B) five frog intermediate pituitary acid 
extracts from Figure 11 were separately pooled, concentrated and redissolved in 0.2 ml of 
0.1% trifluoroacetic acid (Buffer A) prior to fractionation on a Beckman C-18 ODS 
ultrasphere 5 µm column.  The column was equilibrated in 0.1% trifluoroacetic acid 
(Buffer A) and eluted with the 0.1% trifluoroacetic acid/80% acetonitrile (Buffer B) 
( ) gradient as illustrated.  Column fractions were analyzed with the C-terminal α-
MSH RIA ( ).  The following synthetic standards were chromatographed separately 
as reference: frog ACTH(1-13)NH2 (desacetyl-α-MSH) and frog N-acetyl-ACTH(1-
13)NH2 (α-MSH).  Immunoreactive forms of α-MSH-related products are individually 










12B) frog intermediate pituitaries from Figure 11 revealed a prominent peak of α-
MSH immunoreactivity in each case that eluted with a retention time of 22.5 min and 25 
min, respectively.  This immunoreactive form respectively represented 54.2% and 65.8 of 
the total immunoreactivity recovered in the former and latter case.  This immunoreactive 
form did not coelute with identical retention times as the synthetic mammalian synthetic 
standards used; however, this peak of α-MSH-related immunoreactivity represents 
ACTH(1-13)NH2 (desacetyl-α-MSH) as deduced by studies of the N-acetylation of α-
MSH in the intermediate pituitary of X. laevis (Dores et al., 1991; Martens et al., 1991).  
The frog ACTH(1-13)NH2 elutes with a distinct retention time from the mammalian form 
due to the position 1 Ala in contrast to Ser at this position in the mammalian counterpart 
(Dores et al., 1991; Martens et al., 1981).  The minor peaks of immunoreactivity 
observed between 18.5-20.5 min (39.7%) (Figure 12A) and 21.5-23.5 min (34.2%) 
(Figure 12B) represent oxidized forms of frog ACTH(1-13)NH2. 
Reversed-phase HPLC Analysis of S. tropicalis Intermediate Pituitary N-acetyl-β-
endorphin(1-8)-related Material 
 
 Likewise, the peak of N-acetyl-β-endorphin(1-8) material from S. tropicalis 
intermediate pituitary were similarly analyzed by reversed-phase HPLC (Figure 13).  In 
the two pools of eight (Figure 13A) and five (Figure 13B) frog intermediate pituitaries 
analyzed from Figure 11, a major peak and minor peak of N-acetyl-β-endorphin(1-8)-
related immunoreactivity can be observed.  The major peak eluted with a retention time 
of 23 min and 25 min in the former and latter case, respectively, and is identical to the 









Figure 13.  Reversed-phase HPLC analysis: N-acetyl-β-endorphin(1-8)-sized material 
from S. tropicalis intermediate pituitaries.  Aliquots from fractions corresponding to the 
N-acetyl-β-endorphin(1-8)-sized -sized material from the replicates of (A) eight and (B) 
five frog intermediate pituitary acid extracts from Figure 11 were separately pooled, 
concentrated and redissolved in 0.2 ml of 0.1% trifluoroacetic acid (Buffer A) prior to 
fractionation on a Beckman C-18 ODS ultrasphere 5 µm column.  The column was 
equilibrated in 0.1% trifluoroacetic acid (Buffer A) and eluted with the 0.1% 
trifluoroacetic acid/80% acetonitrile (Buffer B) ( ) gradient illustrated in the figure.  
Column fractions were analyzed with the N-terminal β-endorphin RIA ( ).  The 
following synthetic standards were chromatographed separately as reference: NAc-β-
end(1-8) (Xenopus laevis N-acetyl-β-endorphin(1-8)).  Immunoreactive forms of N-
acetyl-β-endorphin(1-8)-related products are individually labeled as oxidized frog N-








This peak was accordingly identified as N-acetyl-β-endorphin(1-8) and represented 93.9% 
(Figure 13A) and 91.3% (Figure 13B) of the total immunoreactivity recovered from the 
two pools of frog intermediate pituitaries.  The minor peak eluted at a retention time of 
21 min (6.1%) and 23 min (8.7%) in the former and latter case, respectively, and 
represents oxidized forms of N-acetyl-β-endorphin(1-8) as deduced from reports on 
oxidation studies (Dores and Rothenberg, 1987; Dores et al., 1991). 
Observations of Steady-state Levels of POMC-derived Products in S. tropicalis 
Anterior Pituitary 
 
Steady-state levels of POMC-derived peptides were also assessed due to the 
availability of S. tropicalis anterior pituitaries following tissue extraction.  Dried column 
fractions following gel filtration fractionation of anterior pituitary acid extracts were 
similarly assessed using the C-terminal β-endorphin and the midregion-specific ACTH 
RIAs (Figure 14).  Two discernible peaks of C-terminal β-endorphin immunoreactivity 
were observed.  The first peaked at a Kav value of 0.17 and 0.17 in the pools of eight 
(Figure 14A) and 10 frogs (Figure 14B), respectively.  The corresponding apparent 
molecular weight of 9 kDa suggests the detection of β-LPH-sized products.  The second 
and principal peak of β-endorphin-related immunoreactivity was found at Kav values of 
0.59 and 0.5 from the duplicates analyzed, respectively, and eluted with an apparent 
molecular weight of 3.5 kDa and is consistent with that of β-endorphin(1-27/31)-sized 
material.  In contrast, very low levels of ACTH(1-39)-sized products were detected 








Figure 14.  Sephadex G-50 (1x40 cm) chromatography: Steady-state levels of S. 
tropicalis anterior pituitary POMC-derived peptides.  Acid extracts from pools of (A) 
eight and (B) 10 frog anterior pituitaries were separately fractionated and aliquots were 
screened by the Midregion ACTH RIA ( ), C-terminal β-endorphin RIA ( ) and 
C-terminal α-MSH RIA ( ).  Specifically, 4.5 kDa ACTH-sized material (Kav = 0.42, 
0.45), 9 kDa β-LPH-sized material (Kav = 0.16), 3.5 kDa β-endorphin(1-27/31)-sized 
material (Kav = 0.59, 0.54) and1.5 kDa α-MSH-sized material (Kav = 0.8, 0.81) were 
detected.  Corresponding Kav values are indicated above the peaks of immunoreactivity.  
Void (VO) and total (VT) volumes were marked by BSA and β-mercaptoethanol, 
respectively.  Both markers were detected spectrophotometrically at A280.  Figure 










0.48 and 0.45 from the two pools of frog anterior pituitaries analyzed, which 
corresponded to an apparent molecular weight of 4.5 kDa. 
Because ACTH(1-39)-sized products were not observed in equimolar amounts 
with C-terminal β-endorphin-related material, relevant column fractions of anterior 
pituitary extracts were additionally screened by the C-terminal α-MSH RIA (Figure 14).  
Unexpectedly, a prominent peak of immunoreactivity was detected at Kav values of 0.80 
and 0.79 in the duplicates analyzed.  The apparent molecular weight of 1.5 kDa suggests 
that a large proportion of ACTH was further processed into α-MSH-sized material within 
the anterior pituitaries of the sexually mature female S. tropicalis.  Per anterior pituitary, 
there was 0.93 ± 0.2 pmol (n = 2) of C-terminal β-endorphin immunoreactivity, including 
β-LPH-sized material.  ACTH(1-39)-sized products (0.12 ± 0.07 pmol/anterior pituitary, 
n = 2) together with α-MSH-sized forms (1.27 ± 0.5 pmol/anterior pituitary, n = 2) 
summed to produce near equimolar amounts with that of the β-endorphin-related material.  
Because α-MSH immunoreactivity was detected in significant proportions, the possibility 
of contamination from the intermediate pituitaries during the extraction process is made 
less likely. 
Summary of S. tropicalis Pituitary POMC-derived Peptides and Comparison to 
Other Amphibians 
 
As eluded earlier, the findings of the steady-state levels of S. tropicalis 
intermediate pituitary POMC-derived peptides are largely in agreement with the reported 




pituitary processing pattern of POMC is unorthodox and contrasts that of X. laevis 
(Kurabuchi and Tanaka, 1996).  Specifically, the detection of α-MSH-related 
immunoreactivity within the anterior pituitaries is an unusual although not unprecedented.  
Prior studies have demonstrated a developmental regulation pattern of POMC processing 
in the anterior pituitaries of the tiger salamander, Ambystoma tigrinum (Dores et al., 1989, 
1990).  Specifically, these amphibians produce α-MSH-related material (ACTH(1-
13)NH2) in near equimolar amounts with that of ACTH in premetamorphic stages; 
however, ACTH becomes the predominant end-product in the post-metamorphic adult 
anterior pituitary (Dores et al., 1989, 1990).  The processing of ACTH into ACTH(1-
13)NH2 has been observed in the anterior pituitary corticotropes of adult axolotls 
(Ambystoma mexicanum) (Dores et al., 1993), an amphibian that matures sexually 
without undergoing metamorphosis.  Moreover, immunohistochemical studies have 
revealed that α-MSH, if detectable at all, make up only a small population of the anterior 
pituitary corticotrope cells, such is the case for Bufo japonicas formosus (Kurabuchi and 
Tanaka, 1996). 
In the case of the sexually mature female S. tropicalis, the detection of steady-
state levels of α-MSH in the anterior pituitaries represents an unexpected preliminary 
result and warrants further studies.  First and foremost, these observations require 
verification by other techniques.  Specifically, colocalization studies employing 
immunohistochemical staining of frog pituitaries using ACTH- and α-MSH-specific 
antiserum would help address the issue of possible contamination.  Moreover, because 




in corticotrope cells of the anterior pituitary.  However, this was not observed for Rana 
brevipoda porosa nor Buergeria japonica, as PC2 did not colocalize with α-MSH in the 
corticotropes (Kurabuchi and Tanaka, 1996).  Nonetheless, the possibility of differential 
expression of PC2 in the S. tropicalis anterior pituitary can be assessed using QRT-PCR 
studies of amphibian PC1/3, PC2 and POMC; however, only immunohistochemistry 
techniques can resolve whether there is consistent colocalization of PC2 with POMC-
derived products.  Lastly, studies on the steady-state levels of POMC-derived peptides 
from the pituitaries during the developmental stages of S. tropicalis might elucidate 
whether the presence of anterior pituitary α-MSH-related immunoreactive material is a 
neotenic trait. 
Expression of Wild-type S. tropicalis POMC and Analysis of αTC1.9 Cells 
 A population of αTC1.9 cells was transiently transfected with the wild-type S. 
tropicalis POMC construct by nucleofection.  The transfected α-cells displayed a 
cytoplasmic punctuate Cy3 staining pattern that encompassed the DAPI-stained nuclei 
(Figure 15), and most likely correspond to the dense core vesicles of the regulated 
secretory pathway.  Typical transfection efficiencies of 71.75 ± 3.84% were observed 
(Figure 15), which was deemed satisfactory for subsequent biochemical analysis.  In 
contrast, no punctuate staining patterns were observed in control non-transfected α-cells, 
suggesting that αTC1.9 cells do not express endogenous POMC. 
 Biochemical tests employing heterologous RIAs were used to determine the 





Figure 15.  Immunocytochemical staining of αTC1.9 cells nucleofected with the wild-
type S. tropicalis POMC construct (left panel).  Non-nucleofected α-cells are shown as a 







poly-L-lysine-coated 2-well chamber slides and fixed with 4% paraformaldehyde.  The 
fixed cells were then permeabilized and subsequently stained with guinea pig anti-rat 
POMC antiserum followed by donkey anti-guinea pig antiserum conjugated to Cy3 (red).  
The cells were then mounted in hard-set Vectashield® with DAPI (blue).  Relative to the 
control cells, wild-type POMC-nucleofected α-cells display a cytoplasmic punctuate 




C-terminal β-endorphin RIA 
 









Midregion ACTH RIA 
 
 
Figure 16.  Radioimmunoassay (RIA) analysis of non- transfection (control) αTC1.9 cells 
( ) and αTC1.9 cells transfection with the wild-type S. tropicalis POMC construct ( ).  
Aliquots of 50 µl of the corresponding concentrated acid extracts obtained from 1 x 10
6
 
cells in each case were separately dried down and screened using the (A) C-terminal β-
endorphin RIA, (B) the C-terminal α-MSH RIA and (C) the midregion ACTH RIA.  The 
corresponding standard curves are shown for reference ( ) and the following synthetic 
standards were used in the respective RIAs: human (A) ACTH(1-39), (B) human β-
endorphin(1-31) and (C) mammalian α-MSH.  The experiment is representative of 
duplicates.  No POMC-related immunoreactivity was observed in the control α-cells.  
Unlike ACTH-related immunoreactivity, C-terminal β-endorphin-related and α-MSH-
related immunoreactivity were quantitatively detectable in the wild-type POMC-







staining.  Specifically, aliquots of concentrated acid extracts from wild-type S. tropicalis 
POMC- transfection and control αTC1.9 cells were separately analyzed by the midregion 
ACTH, C-terminal β-endorphin and C-terminal α-MSH RIAs (Figure 17).  In control α-
cells, POMC-related immunoreactivity was not detectable (Figure 16); however, β-
endorphin-related (Figure 16) and α-MSH-related (Figure 16) but not ACTH-related  
(Figure 16C) immunoreactivity were quantitatively detectable in the acid extracts of the 
wild-type POMC-nucleofected α-cells. 
These radiochemical data consequently reinforce the observation that the αTC1.9 
cells were successfully transfected with and expressed the wild-type S. tropicalis POMC 
construct.  Additionally, the expression of the construct was in sufficient quantities 
permissive for biochemical studies.  Due to the specificities of the antiserum employed in 
the detection of the POMC-derived peptides, the α-cells were deduced to possess the 
relevant posttranslational processing and modification machinery necessary for the 
maturation of the end-products, such as C-terminal amidation of the α-MSH-sized 
material.  While ACTH-related immunoreactivity was not detectable at the aliquot size 
analyzed, this observation is consistent with the predominant expression of PC2 in the 
αTC1.9 cell line (Ugleholdt et al., 2006).  The broader spectrum activity of PC2 is 
involved in the more extensive processing of POMC (Benjannet et al., 1991), such as that 
observed in the intermediate pituitaries where ACTH represents a minor end-product 
subsequent to the liberation of α-MSH.  As such, this scenario might similarly be evinced 




Gene expression analysis by QRT-PCR of both control α-cells and α-cells 
transfected with both wild-type and mutant constructs showed the detection of mice PC2 
and glucagon whereas PC1/3 levels were quantitatively undetectable (Figure 18).  The 
levels of mice PC2 appeared comparable across all conditions, as was the case for 
endogenous glucagon.  Additionally, S. tropicalis POMC was quantitatively detectable 
only in the transfected cells (Figure 18). 
Steady-state Analysis of Posttranslational Processing of Wild-type S. tropicalis 
POMC in αTC1.9 Cells 
 
Acid extracts of wild-type S. tropicalis POMC-nucleofected αTC1.9 cells were 
fractionated by gel filtration as previously described and column fractions were analyzed 
using the C-terminal α-MSH and β-endorphin RIAs.  The N-acetyl-specific β-endorphin 
RIA was also employed.  No peak of β-LPH-sized material was observed (Figure 19).  
However, immunoreactivity corresponding to β-endorphin(1-27/31)-sized material (Kav = 
0.53 and 0.54) and N-acetyl-β-endorphin(1-8)-sized forms (Kav = 0.81 and 0.85) were 
identified in the duplicates analyzed (Figure 19).  These products eluted with an apparent 
molecular weight of 3.5 kDa and 1 kDa, respectively.  Additionally, the peak of α-MSH-
related immunoreactivity was found at a Kav value of 0.78 and had an apparent molecular 
weight of 1.5 kDa (Figure 19).  Altogether, α-MSH-related immunoreactivity (4.55 ± 
0.19 pmol/10
6
 cells, n = 2) was found in near equimolar amounts with the β-endorphin(1-
27/31)-sized and N-acetylated β-endorphin(1-8)-sized material, which averaged 3.43 ± 
0.16 and 1.67 ± 0.054 pmol/10
6





Figure 18.  Gene expression analysis of control and transfected αTC1.9 cells.  The α-cells 
were transfected with either wild-type or mutant S. tropicalis POMC constructs.  Levels 
of endogenous mice PC2 and glucagon but not PC1/3 were detectable in both the control 
and transfected cells; however, only S. tropicalis POMC was only detectable in the latter.  
Histograms represent the normalized fold expression ± SD with mice GAPDH serving as 





endorphin(1-8)-sized form was N-acetylated, as noted earlier in the frog intermediate 
pituitary. 
Reversed-phase HPLC Analysis of α-MSH-related Material from Wild-type S. 
tropicalis POMC-transfected αTC1.9 Cells 
 
The α-MSH-related material from the duplicates were separately prepared for 
reversed-phase HPLC analysis to determine the extent of N-acetylation of the frog α-
MSH-sized products following posttranslational processing and modification events in 
the transfected αTC1.9 cells (Figure 20).  Oxidized forms of ACTH(1-13)NH2, which 
eluted with retention times between 21-23 min in the duplicates, and immunoreactive 
forms corresponding to frog ACTH(1-13)NH2 (25 min and 24 min) were detected.  The 
oxidized form represented 11.4% (Figure 20A) and 22.1% (Figure 20B) of the total α-
MSH-related immunoreactivity recovered, respectively.  On the other hand, ACTH(1-
13)NH2 represented 38.4% (Figure 20A) and 36.9% (Figure 20B) of the total α-MSH-
related immunoreactivity recovered.  Additionally, two additional peaks of α-MSH 
immunoreactivity were also detected.  Based on analysis of the N-acetylation mechanism 
of X. laevis α-MSH (Martens et al., 1981), the peak eluting at a retention time of 32.5 
min (17.9%) (Figure 20A) and 28.5 min (24.8%) (Figure 20B) was found to be similar to 
that observed for frog N-acetyl-ACTH(1-13)NH2 (α-MSH).  Consequently, the peaks 
eluting respectively with a retention time of 28.5 (21.8%) min and 27 min (16.1%) 










Figure 19.  Sephadex G-50 (1 x 40 cm) chromatography: Steady-state levels of S. 
tropicalis POMC-derived peptides from αTC1.9 cells transfected with the wild-type 
POMC construct.  Acid extracts from duplicates (A and B) of nucleofected αTC1.9 cells 
were individually fractionated.  Column fractions were separately screened by the C-
terminal β-endorphin RIA ( ), C-terminal α-MSH RIA ( ) and the N-acetyl β-
endorphin RIA ( ).  Kav values are indicated above peaks of immunoreactivity 
corresponding to 3.5 kDa β-endorphin(1-27/31)-sized material (Kav = 0.51, 0.55), 1.5 kDa 
α-MSH-sized material (Kav = 0.78) and 1 kDa N-acetyl-β-endorphin(1-8)-sized material 
(Kav = 0.81, 0.83).  Void (VO) and total (VT) volumes are marked by BSA and β-










Reversed-phase HPLC Analysis of N-acetyl-β-endorphin(1-8)-related Material from 
Wild-type S. tropicalis POMC-transfected αTC1.9 Cells 
 
Reversed-phase HPLC analysis of the peak of N-acetyl-β-endorphin(1-8)-sized 
immunoreactivity detected on gel filtration columns revealed immunoreactive forms that 
eluted at retention times of 24 min (Figure 21A) and 23.5 min (Figure 21B).  These forms 
represented 73.1% and 87.8% of the total N-acetyl-β-endorphin(1-8)-related 
immunoreactivity recovered, respectively, and eluted at a retention time identical to that 
of the X. laevis N-acetyl-β-endorphin(1-8) synthetic standard.  The peaks detected at 22.5 
min (Figure 21A) and 20 min (Figure 21B) represent oxidized forms of frog N-acetyl-β-
endorphin(1-8). Accordingly, these oxidized forms account for the remainder of the N-
acetyl-β-endorphin(1-8)-related immunoreactivity recovered. 
Steady-state Analysis of Posttranslational Processing of the R142A (R↓) S. tropicalis 
POMC Construct in αTC1.9 Cells 
 
 Radiochemical analysis of the G-50 column fractions of acid extracts obtained 
from α-cells transfected with the R142A construct demonstrated the detection of β-
endorphin(1-27/31)-sized (Kav = 0.52 and 0.47) and N-acetyl-β-endorphin(1-8)-sized (Kav 
= 0.8 and 0.81) products (Figure 22).  These peaks of immunoreactivity eluted at Kav 
values comparable to those detected in the analysis of the wild-type construct and 
consequently correspond to respective apparent molecular weights of 3 kDa and 1 kDa.  
The peak of α-MSH-related immunoreactivity, on the other hand, was quantitatively 
undetectable in the range of fractions where the 1.5 kDa-sized material was detected 








Figure 20.  Reversed-phase HPLC analysis: α-MSH-sized material from αTC1.9 cells 
transfected with the wild-type S. tropicalis POMC.  Aliquots from fractions 
corresponding to the α-MSH-sized material from the two replicates (A and B) from 
Figure 19 were separately pooled, concentrated and redissolved in 0.2 ml of 0.1% 
trifluoroacetic acid (Buffer A) prior to fractionation on a Beckman C-18 ODS ultrasphere 
5 µm column.  The column was equilibrated in 0.1% trifluoroacetic acid (Buffer A) and 
eluted with the 0.1% trifluoroacetic acid/80% acetonitrile (Buffer B) ( ) gradient as 
illustrated.  Column fractions were analyzed with the C-terminal α-MSH RIA ( ).  
The following synthetic standards were chromatographed separately as reference: frog 
ACTH(1-13)NH2 (desacetyl-α-MSH) and N-acetyl-ACTH(1-13)NH2 (α-MSH).  
Immunoreactive forms of frog (f) α-MSH-related products are individually labeled as 
oxidized frog ACTH(1-13)NH2, frog ACTH(1-13)NH2, oxidized frog α-MSH and frog α-












Figure 21.  Reversed-phase HPLC analysis: N-acetyl-β-endorphin(1-8)-sized material 
from αTC1.9 cells transfected with the wild-type S. tropicalis POMC construct.  Aliquots 
from fractions containing N-acetyl-β-endorphin(1-8)-sized material from two replicates 
from Figure 19 were separately pooled, concentrated and redissolved in 0.2 ml of 0.1% 
trifluoroacetic acid (Buffer A) prior to fractionation on a Beckman C-18 ODS ultrasphere 
5 µm column.  The column was equilibrated in 0.1% trifluoroacetic acid (Buffer A) and 
eluted with the 0.1% trifluoroacetic acid/80% acetonitrile (Buffer B) ( ) gradient as 
illustrated.  Column fractions were analyzed with the N-terminal β-endorphin RIA 
( ).  The following synthetic standards were chromatographed separately as 
reference: NAc-β-end(1-8) (X. laevis N-acetyl-β-endorphin(1-8)).  Immunoreactive forms 
of frog (f) N-acetyl-β-endorphin(1-8)-related products are individually labeled as frog N-









(Figure 22A) and 0.35 (Figure 22B), which correspond to an apparent molecular weight 
of 6 kDa.  This would be consistent with the detection of a JP-alpha-MSH fusion protein.  
This was a consequence of the impaired cleavage at the KR dibasic site due to the 
substitution of alanine for the target arginine (R↓) in position 142.  Between the two 
replicates, C-terminal β-endorphin-related and N-acetyl-β-endorphin(1-8)-related 
immunoreactivity were found at 3.57 ± .51 pmol/10
6
 cells (n = 2) and 1.49 ± 0.01 
pmol/10
6
 cells (n = 2), respectively.  These values were largely in equimolar amounts 
with that of α-MSH immunoreactivity, which averaged 4.63 ± 0.24 pmol/10
6
 cells (n = 2). 
Reversed-phase HPLC Analysis of N-acetyl-β-endorphin(1-8)-related Material from 
αTC1.9 Cells Nucleofected with the R142A (R↓) S. tropicalis POMC Construct 
 
 Reversed-phase HPLC analysis of the N-acetyl-β-endorphin(1-8) immunoreactive 
peak obtained from the relevant G-50 column fractions revealed the detection of N-
acetyl-β-endorphin(1-8)-sized material.  In both duplicates, these peaks eluted with a 
retention time of 24.5 min (Figure 23) similar to that detected for the synthetic X. laevis 
N-acetyl-β-endorphin(1-8).  These accounted for 52.4% (Figure 23A) and 16% (Figure 
23B) of the total N-acetyl-β-endorphin(1-8)-related immunoreactivity recovered.  
Oxidized forms of N-acetyl-β-endorphin(1-8) were found at a retention time of 22.5 min 
and represent the remainder of the recoverable immunoreactivity.  The detection of 
greater amounts of the artificial, oxidized forms suggests overexposure to oxidation 










Figure 22.  Sephadex G-50 (1 x 40 cm) chromatography: Steady-state levels of S. 
tropicalis POMC-derived peptides from αTC1.9 cells transfected with the R142A mutant 
construct.  Acid extracts from duplicates (A and B) of nucleofected αTC1.9 cells were 
individually fractionated.  Column fractions were separately screened by the C-terminal 
β-endorphin RIA ( ), C-terminal α-MSH RIA ( ) and the N-acetyl β-endorphin 
RIA ( ).  Kav values are indicated above peaks of immunoreactivity corresponding to 
3 kDa β-endorphin(1-27/31)-sized material (Kav = 0.52, 0.47) and 1 kDa N-acetyl-β-
endorphin(1-8)-sized material (Kav = 0.8, 0.81).  Immunoreactive α-MSH-related material 
appeared at a Kav of 0.36 and 0.35 with an apparent molecular weight of 6 kDa and is 
consistent with a JP-α-MSH mutant fusion protein.  Void (VO) and total (VT) volumes are 
marked by BSA and β-mercaptoethanol, respectively.  Both markers were detected 













Figure 23.  Reversed-phase HPLC analysis: N-acetyl-β-endorphin(1-8)-sized material 
from αTC1.9 cells transfected with the R142A mutant construct.  Aliquots from fractions 
containing N-acetyl-β-endorphin(1-8)-sized-sized material from the replicates in Figure 
22 were separately pooled, concentrated and redissolved in 0.2 ml of 0.1% trifluoroacetic 
acid (Buffer A) prior to fractionation on a Beckman C-18 ODS ultrasphere 5 µm column.  
The column was equilibrated in 0.1% trifluoroacetic acid (Buffer A) and eluted with the 
0.1% trifluoroacetic acid/80% acetonitrile (Buffer B) ( ) gradient illustrated in the 
figure.  Column fractions were analyzed with the N-terminal β-endorphin RIA ( ).  
The following synthetic standards were chromatographed separately as reference: NAc-β-
end(1-8) (X. laevis N-acetyl-β-endorphin(1-8)).  Immunoreactive forms of frog N-acetyl-
β-endorphin(1-8)-related products are labeled as oxidized frog N-acetyl-β-endorphin(1-8) 












Steady-state Analysis of Posttranslational Processing of the K141A (K0) S. tropicalis 
POMC Construct in αTC1.9 Cells 
 
 The same chromatographic and radiochemical methodologies were employed in 
the analysis of the steady-state levels of the K141A mutant construct following 
transfection in the α-cells.  Analogous to the scenario observed for the R142A mutant, 
both β-endorphin(1-27/31)-sized (Kav = 0.5) and N-acetyl-β-endorphin(1-8)-sized peaks 
(Kav = 0.8 and 0.84) eluted at respective apparent molecular weights of 3 kDa and 1 kDa 
(Figure 24).  Once again, α-MSH-related immunoreactivity only eluted at Kav values of 
0.35 and 0.32 and corresponds to an apparent molecular weight of 6 kDa (Figure 24).  No 
α-MSH-sized material was detected at Kav values corresponding to an apparent molecular 
weight of 1.5 kDa.  As was the case observed with the R142A mutant, alanine 
substitution of the lysine residue at position 141 of the KR↓ cleavage site also prevented 
cleavage.  Overall, C-terminal β-endorphin-related and N-acetyl-β-endorphin(1-8)-related 
immunoreactivity averaged 3.43 ± 0.18 pmol/10
6
 cells (n = 2) and 2.26 ± 0.15 pmol/10
6
 
cells (n = 2), respectively.  Total α-MSH-related immunoreactivity was found at 3.68 ± 
0.12 pmol/10
6
 cells (n = 2). 
Reversed-phase HPLC Analysis of N-acetyl-β-endorphin(1-8)-related Material from 
αTC1.9 Cells Nucleofected with the K141A (K0) S. tropicalis POMC Construct 
 
 N-acetyl-β-endorphin(1-8)-related immunoreactivity was quantitatively 








Figure 24.  Sephadex G-50 (1 x 40 cm) chromatography: Steady-state levels of S. 
tropicalis POMC-derived peptides from αTC1.9 cells transfected with the K141A mutant 
construct.  Acid extracts from two replicates (A and B) of nucleofected αTC1.9 cells 
were individually fractionated.  Column fractions were separately screened by the C-
terminal β-endorphin RIA ( ), C-terminal α-MSH RIA ( ) and the N-acetyl β-
endorphin RIA ( ).  Kav values are indicated above peaks of immunoreactivity 
corresponding to 3.5 kDa β-endorphin(1-27/31)-sized material (Kav = 0.5) and 1 kDa N-
acetyl-β-endorphin(1-8)-sized material (Kav = 0.8, 0.84).  The peak of immunoreactivity 
corresponding to α-MSH-related immunoreactivity appeared at a Kav of 0.35 and 0.32, 
which corresponds to an apparent molecular weight of 6 kDa and is consistent with a JP-
α-MSH mutant fusion protein.  Void (VO) and total (VT) volumes are marked by BSA 
and β-mercaptoethanol, respectively.  Both markers were detected spectrophotometrically 









Steady-state Analysis of Posttranslational Processing of the R137A (R4) S. tropicalis 
POMC Construct in αTC1.9 Cells 
  
 Steady-state analysis of α-cells transfected with the R137A Construct for C-
terminal α-MSH, C-terminal β-endorphin and N-acetyl-β-endorphin(1-8) 
immunoreactivity revealed a processing pattern identical to that observed for the wild-
type POMC construct.  In the duplicates analyzed, β-endorphin(1-27/31)-sized (Kav = 
0.51) and N-acetyl-β-endorphin(1-8)-sized (Kav = 0.83 and 0.86) material eluted with 
apparent molecular weights of 3 kDa and 1 kDa, respectively (Figure 25).  The peak of 
immunoreactivity corresponding to the JP-α-MSH mutant fusion protein was undetected.  
Instead, α-MSH-sized immunoreactive forms eluted with an apparent molecular weight 
of 1.5 kDa (Kav = 0.8 and 0.76) (Figure 25).  Taken together, alanine substitution of 
arginine at position 137 did not have a detrimental effect at the KR↓ cleavage site directly 
N-terminal of the α-MSH peptide sequence.  Altogether, α-MSH-related 
immunoreactivity averaged 5.37 ± 0.07 pmol/10
6
 cells (n = 2) and was found in near 
equimolar amounts with that of C-terminal and N-acetyl-specific β-endorphin-related 
immunoreactive forms, which averaged 4.21 ± 0.21 pmol/10
6
 cells and 0.9 ± 0.14 
pmol/10
6









Figure 25.  Sephadex G-50 (1 x 40 cm) chromatography: Steady-state levels of S. 
tropicalis POMC-derived peptides from αTC1.9 cells nucleofected with the R137A 
mutant construct.  Acid extracts from two replicates (A and B) of nucleofected αTC1.9 
cells were individually fractionated.  Column fractions were separately screened by the 
C-terminal β-endorphin RIA ( ), C-terminal α-MSH RIA ( ) and the N-acetyl β-
endorphin RIA ( ).  Kav values are indicated above peaks of immunoreactivity 
corresponding to 3.5 kDa β-endorphin(1-27/31)-sized material (Kav = 0.51, 0.55), 1.5 kDa 
α-MSH-sized material (Kav = 0.78) and 1 kDa N-acetyl-β-endorphin(1-8)-sized material 
(Kav = 0.81, 0.83).  Void (VO) and total (VT) volumes are marked by BSA and β-
mercaptoethanol, respectively.  Both markers were detected spectrophotometrically at 











 Endoproteolytic cleavage sites involved in the liberation of peptide hormones 
from their biologically inactive precursors, including S. tropicalis POMC, are typically 
comprised of dibasic or monobasic amino acid residues.  This generalization can be 
further characterized based on the presence or absence of proline at the cleavage site.  
Nonetheless, the mechanism by which an endoprotease selectively processes at certain 
cleavage sites but not others has remained largely elusive. 
 In 1991, a hypothesis introduced the notion of a consensus sequence for the 
processing of peptide precursors at monobasic sites (Devi, 1991).  This proposal, an 
extension of the proline-directed arginyl cleavage mechanism introduced by Schwartz 
(1986), was based on empirical observations and proposed four rules and five tendencies 
required for cleavage at monobasic sites.  For example, it was suggested that a basic 
amino acid is present 3, 5 or 7 residues N-terminal of the cleavage site (Devi, 1991).  The 
other rules and tendencies were empirically-derived based on an analysis of over 100 
prohormone sequences and were capable of predicting not only monobasic but also 
dibasic processing sites (Devi, 1991). 
 In another attempt at predicting the features required for endoproteolytic cleavage, 




in or around the vicinity of regions with a high probability of forming β-turns.  These 
regions of β-turns encompass the basic pair and were suggested to be flanked on either 
side by more ordered secondary structures such as β-sheets and α-helices (Rholam et al., 
1986).  Consequently, this conformational feature might constitute a minimal recognition 
motif by the specific endoprotease(s) (Rholam et al., 1986). 
 In light of the preceding hypothesis, it should be noted that any generalizations 
made about processing events at dibasic cleavage sites must be defined in terms of the 
processing enzymes involved in the cleavage mechanism.  My thesis is focused on the 
cleavage specificities of PCs.  Currently, the seven members of the subtilisin-like PC 
family all preferentially cleave C-terminal of basic residues with the exception of SKI-1, 
which cleaves C-terminal of leucine and threonine residues (Seidah and Chrétien, 1999; 
Seidah et al., 1999).  Additionally, the various PC family members exhibit characteristic 
tissue expression patterns such as the testicular and ovarian germ cell expression of PC4 
(Henrich et al., 2005; Seidah and Chrétien, 1999) or the predominantly neuroendocrine 
expression of PC1/3 and PC2 (Seidah and Chrétien, 1999; Seidah et al., 1999).  
Furthermore, subtilisin-like family members are active within different compartments of 
the secretory pathway.  For example, furin functions exclusively in the constitutive 
pathway in contrast to both PC1/3 and PC2, which function in the regulated secretory 
pathway (Seidah and Chrétien, 1999; Seidah et al., 1999). 









S. tropicalis POMC  
 
[----------------------- Signal Sequence ----------------] 
atgtttcggccactctggggctgttcccttgcaatactcggggcatttatattccatgtcgagaggtgcaaggccagtgcg    81 
M  F  R  P  L  W  G  C  S  L  A  I  L  G  A  F  I  F  H  V  G  E  V  Q  G  Q  C      27 
tgggagagcagccgatgtgcagacctcagcagtgaagatggagttctggaatgcatcaaggcatgtaaaatggacctctcc   162  
W  E  S  S  R  C  A  D  L  S  S  E  D  G  V  L  E  C  I  K  A  C  K  M  D  L  S      54 
                                                         *  [-------- γ1-MSH ---- 
gccgagtcccctgtgtttccgggaaatggacatttgcagcctctgtcggaaagtataagaaaatatgtgatgacccatttc   243 
A  E  S  P  V  F  P  G  N  G  H  L  Q  P  L  S  E  S  I  R  K  Y  V  M  T  H  F      81 
------------]     *  * 
cggtggaataaattcggcagaaggaacagcacagggaacgatgggagcagctcgggctacaaacgcgaagatatttctaat   324    
R  W  N  K  F  G  R  R  N  S  T  G  N  D  G  S  S  S  G  Y  K  R  E  D  I  S  N     108 
taccctgtatttaatctgtttcccgtgagtgacaacatggaacagaacgctcaaggcgacaacatggaaggggaacccttg   405 
Y  P  V  F  N  L  F  P  V  S  D  N  M  E  Q  N  A  Q  G  D  N  M  E  G  E  P  L     135 
                     [--------- α-MSH -------------------]     *  *  * 
               *  *  [------------------------------------------ ACTH ----------- 
gacaggcaggagaataagagagcctactctatggagcacttccgatgggggaaacccgttgggagaaagaggaggcccatt   486  
D  R  Q  E  N  K  R  A  Y  S  M  E  H  F  R  W  G  K  P  V  G  R  K  R  R  P  I     162 
------------------------------------------------------]  *  * 
aaggtgtaccccaacggagtggaagaagagtccgctgagaactaccccatggagctaagaagagaattatccctagaactc   567 
K  V  Y  P  N  G  V  E  E  E  S  A  E  N  Y  P  M  E  L  R  R  E  L  S  L  E  L     189 
                                                               *  *  [-- β-MSH --       
gactatccggatatcgaccttgatgaggacattgaagacaacgaagtggaaagcgctctaacgaaaaagaatggaaactac   648 
D  Y  P  D  I  D  L  D  E  D  I  E  D  N  E  V  E  S  A  L  T  K  K  N  G  N  Y     216 
                                             [- β-endorphin(1-8)--]  * 
------------------------------------]  *  *  [----------------------------------- 
aggatgcatcacttccgatggggcagcccacccaaagataagagatatgggggatttatgactcctgagcggagccagaca   729 
R  M  H  H  F  R  W  G  S  P  P  K  D  K  R  Y  G  G  F  M  T  P  E  R  S  Q  T     243 
----------------- β-endorphin ------------------------] 
cctctaatgactcttttcaaaaatgccatcatcaaaaacacccacaaaaagggtcagtag                        789 
P  L  M  T  L  F  K  N  A  I  I  K  N  T  H  K  K  G  Q  STOP                       263 
         
Peptide Hormone Polypeptide Sequence at 







γ1-MSH N-terminal cleavage site PLSESIRKYV no β-turn 
γ1-MSH C-terminal cleavage site RWNKFGRRNS β-turn 
α-MSH N-terminal cleavage site LDRQENKRAY β-turn 
α-MSH C-terminal cleavage Site WGKPVGRKRR β-turn 
ACTH C-terminal cleavage site NYPMELRREL no β–turn; α-helix 
β-endorphin N-terminal cleavage site GSPPKDKRYG β-turn 
 
Figure 28.  Secondary structure predication of S. tropicalis POMC.  The nucleotide and 
polypeptide sequence of S. tropicalis POMC is shown along with endoproteolytic 
cleavage sites and peptide hormone sequences.  The table highlights the predicated 
secondary structures around cleavage sites at either the N- or C-terminus of various 
peptide hormone regions.  Secondary structure predictions were accomplished using the 





polypeptide sequence encompassing this particular cleavage site, LDRQENKRAY, is 
predicted to adopt a β-turn formation and the relevant residues underlined (Figure 28).  
Observations of other cleavage sites in the S. tropicalis POMC sequence reveals that β-
turn structures were predicted to occur in the immediate vicinity of four out of the six 
cleavage sites examined (Figure 28).  This consequently gives credence to the hypothesis 
which advocated the importance of β-turns at the cleavage site (Rholam et al., 1986). 
 The purpose of the project was to test the general recognition motif of (R/K)-(X)n-
(R/K)↓ where n = 0, 2, 4 or 6 and X is any amino acid except Cys or Pro (Seidah and 









 were important in the PC2-mediated cleavage process.  In other 
words, only R
142
 was believed to be the pivotal basic residue for endoproteolysis.  
However, based on cell culture studies with alanine substitutions of S. tropicalis POMC 
in the predominantly PC2-expressing αTC1.9 cell line, chromatographic and 
radioimmunoassay techniques revealed that substitution of K141 and R142 with alanine 
obliterated processing at this dibasic site.  Consequently, a JP-α-MSH mutant fusion 
protein with an apparent molecular weight of 6 kDa was generated (Figure 29).  In 
contrast, both the wild-type POMC and R137A mutant construct did not affect cleavage 
at this dibasic site and produced the α-MSH segment that had an apparent molecular 
weight of 1.5 kDa (Figure 29).  Taken together, these data support the general recognition 
motif of (R/K)-(X)n-(R/K)↓ where n = 0, 2, 4 or 6 and X is any amino acid except Cys, as 
proposed by Seidah and Chrétien (1999), only if n = 0.  These findings also support the 





Figure 29.  Representation of wild-type and mutant S. tropicalis POMC cleavage events 
in the αTC1.9 cells, which expresses predominantly PC2.  Illustrated only is the 




 cleavage site intervening the JP fragment of the N-terminal 
region and the α-MSH segment, the first 13 amino acid residues of ACTH.  Compared to 
wild-type frog POMC, K141A and R142A but not R137A compromised endoproteolytic 
cleavage and produced a JP-α-MSH mutant fusion protein.  Cleavage to liberate full-
length β-endorphin(1-27/31) and the truncated N-acetyl-β-endorphin(1-8) were not 
affected between the wild-type nor mutant POMC constructs; consequently, this event is 
























sequence (Figure 28) has the propensity for forming a β-turn structure.  
These privileged secondary structures were thought to be important in the recognition 
process for cleavage by endoproteases (Rholam et al., 1986).  In a test of this hypothesis, 









individually substituted by alanine.  However, analysis of this construct demonstrated 
that the α-MSH segment with an apparent molecular weight of 1.5 kDa was fully 
liberated (Figure 30).  The 3.5 kDa β-endorphin form was also detected; however, the 
truncated N-acetyl-β-endorphin(1-8) product was not detectable.  Secondary structure 
prediction showed that the 4A construct contained high propensity α-helix-formation 
instead of the original β-turn, such was the case for wild-type S. tropicalis POMC (Table 
2).  The interpretation of this result is that that beta-turn structure induced by the wild-




 cleavage site in S. tropicalis POMC 
was not vital in the recognition process for cleavage by PC2 in the α-cells. 
Ultimately, the goal will be to discern the molecular basis for the tissue-specific 
processing of POMC observed in the PC1/3-expressing anterior pituitary and 
predominantly PC2- (and PC1/3)-expressing intermediate pituitary.  For the latter 
purpose, cell lines studies in the αTC1.9 cell line will be important for discerning the role 




cell line will have to be selected.  This cell line ideally should express endogenous PC1/3, 
otherwise the cell line will have to be cotransfected with the PC construct of interest in 
conjunction with the S. tropicalis POMC construct. 




 cleavage site 
in S. tropicalis POMC truly represents a dibasic cleavage site.  Specifically, it was 




 prevented endoproteolysis at 
this site and resulted in a JP-α-MSH fusion protein.  However, the question remains open 
on the outcome of substitution of K
141
 with a polar amino acid, such as asparagine.  Will 
there be cleavage at this site?  If so, this would redefine the dibasic site at the junction 







Figure 30.  Figure 25.  Sephadex G-50 (1 x 40 cm) chromatography: Steady-state levels 
of S. tropicalis POMC-derived peptides from αTC1.9 cells nucleofected with the 4A 
mutant construct.  Acid extracts from only one replicate of nucleofected αTC1.9 cells was 
individually fractionated.  Column fractions were separately screened by the C-terminal 
β-endorphin RIA ( ), C-terminal α-MSH RIA ( ) and the N-acetyl β-endorphin 
RIA ( ).  Kav values are indicated above peaks of immunoreactivity corresponding to 
3.5 kDa β-endorphin(1-27/31)-sized material (Kav = 0.59) and 1.5 kDa α-MSH-sized 
material (Kav = 0.77).  However, 1 kDa N-acetyl-β-endorphin(1-8)-sized material was 
quantitatively undetectable.  Void (VO) and total (VT) volumes are marked by BSA and 
β-mercaptoethanol, respectively.  Both markers were detected spectrophotometrically at 





S. tropicalis POMC construct Polypeptide Sequence at N-
terminal α-MSH Cleavage 




Structure at Cleavage 
Site 
Wild-type GEPLDRQENKRAYSMEH β-turn 
4A Mutant GEPLDAAAAKRAYSMEHF No β-turn; α-helix 
 





cleavage site.  Compared to the wild-type construct, the sequence directly N-terminal of 
the KR dibasic cleavage site in the 4A mutant is predicated to adopt an α-helix instead of 
a β-turn.  Secondary structure predictions were made using the Server for β-turn Types 
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